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SUMMARY 
Information resources hold often one of the main hidden assets in organizations and for that 
reason, if properly managed and reused, can be a real carrier of value. The purpose of this 
thesis is to discuss and present a logical method for approaching the valuation of information 
assets considering risk related aspects of not having the right information, in the right format 
at the right time when an undesirable event occurs. Consequently, knowing the value of 
information can prove an important factor when deciding on building IT/IS environment that 
supports full utilization and business benefits of the information assets. The cases presented in 
this work are significant to AstraZeneca as well as to the pharmaceutical industry as a whole, 
portraying the use of clinical research information in relation to risk, supporting the 
importance of valuing clinical research information and promoting its reusability as a valuable 
organizational resource.  
 
Given the nature of clinical research (CR) information arriving at a valuation, whether 
qualitative or quantitative is highly subjective and based on individual or collective 
assessment. Five reasons for valuing CR information are identified and discussed; exclusive 
possession, utility, cost or cost of recreation, potential liability and operational impact, since 
information valuation is multidimensional in nature and each reason can represent a potential 
qualitative and/or quantitative information value. Clinical research information can be said to 
hold significant value when it comes to supporting risk and issue management. Knowing that 
CR information is accessible and accurate facilitates the management of issues and minimizes 
the risk for liability and operational impact as is supported with case studies. The work 
resulted in a conclusion that the effort to value information is not entirely problem free, 
although going through the method presented it is possible to approach information value. 
 
The report is written in English. 
 
 
 
Keywords: Information, value of information, risk management, clinical research 
information. 
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SUMMERING 
Information kan ofta ses som en viktig men osynlig tillgång inom organisationer och om den 
är rätt administrerad och återanvänd kan information besitta mycket värde. Syftet med denna 
uppsats är att diskutera och presentera en logisk metod för att närma sig värdet av 
informationstillgångar med hänsyn till risk relaterade aspekter av att inte ha rätt information i 
rätt format vid rätt tidpunkt när en oönskad händelse uppstår. Därför kan det vara viktigt att 
veta hur värdefull informationen är när beslut tas om att bygga en IS/IT miljö som skall stödja 
utnyttjandet och affärsmöjligheten av informationstillgångarna. Fallen som presenteras i 
uppsatsen är viktiga för AstraZeneca men även för läkemedelsbranschen som helhet då dom 
visar hur klinisk information används i relation till risk. Detta stödjer viktigheten av att 
värdera klinisk information och återanvända den som en viktig tillgång i organisationen.  
  
På grund av klinisk informations natur är värderingen, kvalitativ eller kvantitativ, väldigt 
subjektiv och baserad på individuella eller kollektiva bedömningar. Fem andledningar för att 
värdera klinisk information är introducerade och diskuterade; exclusive possession, utility, 
cost or cost of recreation, potential liability och operational impact, eftersom värdering av 
information är multidimensionell i sin natur och varje anledning kan representera ett 
kvalitativt och/eller kvantitativt värde. Klinisk information kan anses ha signifikant värde när 
det gäller att stödja risk och ”issue” hantering. Medvetenheten om att klinisk information är 
tillgänglig och pålitlig understödjer hanteringen av ”issues” och minimerar risken för liability 
och operational impact, vilket fallstudien visar. Arbetet resulterade bland annat i att värdering 
av information inte är problemfri, även om det är möjligt att närma sig värdet av information 
genom att följa den modell som presenteras. 
  
Rapporten är skriven på engelska 
 
 
  
Nyckelord: Information, värdet av information, risk management, klinisk information.  
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1 Background 
The chapter provides a background to the subject and why the study is relevant. It 
presents the problem statement of the thesis and concludes with the delimitations and 
expected results of this work. 
 
1.1 Introduction  
Few organizations have realized the full potential of their information assets, although 
most consider their information to be essential to the operation. Information residing 
in different sources within organizations are most often believed to hold significant 
value but rarely is there any methodological valuation done. For that reason, it is 
important to consider the value of information and related risk aspects (not having the 
right information, in the right format at the right time), as important factors when 
deciding on building an information environment that supports full exploitation and 
business benefits of the information assets. Knowing the value of the information 
assets can lead to having a better understanding of the most and least valuable 
information in the organization as well as greater awareness of how information is 
being used, its usability and reliability.  
 
It is suggested that there is a need to maintain a balance between information assets 
value, risk and the commitment to IT/IS in order to steer and not to over invest in 
IT/IS. This requires that organizations determine how they approach valuing 
information and for what reason. However, the task of measuring the value of 
information has continued to be difficult to a large extent. Although, some success has 
been achieved in measuring the exchange value of information, whereas its value in 
trade can be considered to follow the economic laws of supply and demand, but the 
quantitative value of information in use within an organization has been somewhat 
intangible. 
 
Therefore the approach of this thesis is to establish information as a concept in order 
to set the stage for how information is interpreted, valuated, increased in value and 
finally approach how to account for and minimize risk aspects of clinical research 
information. 
  
1.2 Problem description 
In order to have the ability to determine if an IT project is worth the risk, economical 
and time consuming effort, a process for valuing the information itself, rather than the 
frequently applied technology focus, could prove more rewarding to an organization. 
Therefore the following problems are identified as being relevant in relations to 
information as an important organizational resource. 
 
Little understanding from management regarding the real value of information and 
information not fully exploited 
The management of information and the underlying data has not been given the 
highest priority of top management within organizations. This has even been true 
when it comes to how information and data is managed within the pharmaceutical 
industry where “paper” documents of valuable information and data, e.g. from clinical 
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trials, have not been managed as successfully as other parts of the business (Uehling, 
2002). Taking into consideration how valuable this information is for reuse and can 
enhance further discovery, shorten the development time and time to market, it should 
be regarded as a high priority by top management to focus on improving the 
information management and exploitation within the organization.   
 
Not a positive relationship between IT investment and financial performance 
Although it is widely accepted that information technology has transformed and 
assisted organizations to reach new heights in performance and productivity it is also 
accepted that this has been done at perhaps unnecessarily high cost. According to 
Glazer (1991), Carr (2003), Davenport (1994), Strassmann (2003) et al., there are 
number of studies suggesting that there is little, if any, relationship between the 
increase in IT spending and a positive financial performance. Therefore it is suggested 
by Glazer (1991), Moody and Walsh et al. (1999), that for organizations to 
successfully implement their IT strategy they should focus on the information and its 
value rather than on technology, potential benefits and return on investment (ROI) 
calculations (which are often misleading and done by the project sponsor).  
 
Risk of financial liability due to unavailable information 
There is an increasing demand for improving the management of information assets 
within organizations. This is especially true within the pharmaceutical industry where 
the driving force for better management of clinical trial information and data comes 
from the fear of legal liability. Where, the consequences of not acting on information 
that suggests harmful effects can be deemed as obvious liability issue in a legal action. 
Furthermore the proactive usage of information can support decision making and 
increase creativity. Therefore, it can be suggested that better handling and proactive 
thinking when it comes to managing information and data from clinical trials can 
assist in earlier detection and resolution of a potential critical situation rising from the 
effect of a drug. (Uehling, 2002) 
 
Information strategy not in line with information value 
Organizations that don’t have an information value focus in their IT strategy are 
missing out on using the information value to guide their IT strategic planning, cost 
justify IT investments and measure the overall effectiveness of IT (Moody & Walsh, 
1999). Once organizations have understanding of the value of information assets, 
Strassmann (1996) recommends that they establish a strategic framework for the asset 
governance.  
 
Within AstraZeneca information reuse needs to be addressed 
Within the Medical informatics group at AstraZeneca the subject of valuing 
information has been addressed to some extent. Information has been identified as a 
resource that is valuable, therefore deserving special attention in order to reach its full 
potential for the organization. The use and reuse of information assets is considered to 
be the main indicator for information value when estimating its real business 
contribution. As an example, a successful drug development process creates 
considerable value, but actual revenues may take years to materialize. Under the 
development process there is no registration of value created, only direct cost 
associations (Bernhut, 2001). Information has all the characteristics of an intangible 
asset (see 2.1.2) and as such its unique characteristics do not prevent it from being 
used simultaneously by others in another case. Therefore a method for valuing 
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information assets can be used within AstraZeneca to support building a better 
information-sharing environment and promote information reuse. 
 
1.3 Purpose and question at issue 
Referring to the discussion in the problem description above, the purpose of this thesis 
is to discuss and present a logical method for approaching the valuation of 
information assets considering risk related aspects of not having the right information, 
in the right format at the right time when an undesirable event occurs. Furthermore the 
purpose is to explore how information value can be increased in order for the 
organizations to harness the full potential of their information assets through reuse for 
e.g. risk reduction, product discovery, etc. Relevant case studies are included in order 
to establish the link between information valuation and risk aspects. 
 
Although the topics of this thesis have been researched significantly it should not be 
considered complete or the absolute truth for the subject area. 
 
 
 
The question at issue for this thesis is:  
 
 
What is the value of Clinical Research information from a risk analysis 
perspective at AstraZeneca? 
 
 
To better understand and make clear the main question the following underlying 
questions will be answered: 
 
o What methods are there for valuing clinical research information? 
o How does clinical research information support risk and issue management at 
AstraZeneca? 
 
 
1.4 Delimitation 
This thesis is delimited to exploring and addressing methods for organizations to 
value their information assets, considering risk aspects. The theoretical framework 
will also work as delimitation to this thesis where information value and risk aspects 
will be discussed and presented (se chapter 2.2 – 2.4).  
 
Since the problem of this thesis is to focus on the intangible assets of information it 
limits the possibilities of other broader approaches where the focus is on all 
organizational intangible assets e.g. human and knowledge capital. Most widely 
known theories and practical methods of valuing intangible assets don’t focus on 
valuing information as an asset of its own. These methods aim to measure the value of 
e.g. knowledge/intellectual capital to account for in the organizational financial 
statement (Sveiby, 1997; 2001; Edvinsson & Malone, 1997, Strassmann, 1996), 
success of knowledge management initiatives (Sveiby, 1997; Kaplan & Norton, 1992; 
Dhansukhlal & Chaudhry, 2002) and information centers (Skyrme, 2002; Broadbent 
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& Lofgren, 1993) where information is only considered a small part of a larger 
context. Furthermore, the first two categories measure the company’s performance by 
indicators that are based on the strategic objectives of the firm making it difficult to 
isolate the information value.  
 
The purpose of the thesis is not to present an outcome of information value in a 
monetary value but rather highlight possible approaches to the subject of valuing 
information. Furthermore, this thesis does not have a focus on finding the value of 
information from a decision support perspective (Bell, 1991) because of the nature of 
clinical research information.  
 
1.5 Expected results 
The result of this thesis is expected to demonstrate to organizations through examples 
the importance of information valuation from a risk perspective and that organizations 
will appreciate the benefits in the valuation process itself rather than a quantitative 
value of information. The valuation process is expected to lead to greater awareness 
of information being a valuable asset and playing a key role in the organizations IT 
strategy. The result of this thesis should give organizations a broader perspective to 
how information can be valued in different ways as well as being useful to some 
extent when improving information for reuse and defense purposes.  
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1.6 Disposition 
 
Chapter 1 – Introduction. The chapter provides a background to the subject and why 
the study is relevant. It presents the problem statement of the thesis and concludes 
with the delimitations and expected results of this work.  
 
Chapter 2 – Theoretical framework. The information concept is presented and 
discussed. Various views on information value and how to add value to information 
are discussed as well as how risk management relates to information value. 
 
Chapter 3 – Method. The differences between qualitative and quantitative methods 
are discussed followed by a discussion of possible methods for collecting information 
that are relevant to this thesis. The chapter argues for the chosen methods that are 
used in addition to describing the work process for the literature and the case studies. 
The chapter concludes with a discussion on how to deal with uncertainties.  
 
Chapter 4 – Empirical study. The chapter begins with a short presentation of 
AstraZeneca as a company followed by a description of the medical informatics 
department at which the work on this thesis took place. Then the case studies are 
presented as well as their key finding. 
 
Chapter 5 – Analysis. In this chapter the material from the case studies is analyzed 
and put in context with the theoretical framework presented in chapter 2. The cases 
are analyzed from an information value and risk perspective as well as how to 
approach information valuation based on various reasons.  
 
Chapter 6 – Conclusion. This chapter highlights the findings from the analysis 
chapter and puts these in context with the question at issue for this thesis. 
 
Chapter 7 – Discussion. In this chapter relevant issues regarding the work on this 
thesis as well as its conclusions are discussed.  
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2 Literature review 
In this chapter the information concept is presented and discussed. Various views on 
information value and how to add value to information are presented as well risk 
related to information value. 
2.1 Information as a concept 
The definitions of data, information and knowledge are discussed and how they relate 
to each other. Furthermore, a presentation of information attributes and how they 
contribute to the uniqueness of information as an asset.  
2.1.1 Data, information, knowledge  
The relationship between data, information and knowledge has been widely discussed 
and debated in the literature (table 1). There is some confusion in the use of these 
terms but most authors agree that knowledge is the definitive result of the capture of 
data and when context and purpose is applied to data information is produced 
(Coakes, 2003). By applying one’s own terms of reference knowledge is produced 
within the minds of individuals. Toumi (2000) challenges this view and states that 
data emerges after information, which in turn emerges after knowledge. According to 
Stenmark (2002) the three entities influence each other and the value of any of them 
depends on the purpose for which it is to be used. Stenmark states that knowledge is 
required to understand both data and information, but at the same time, data and 
information are important when creating new technologies (knowledge).  
 
When looking at the concept information difficulties arise since information has to do 
with becoming informed and therefore reducing someone’s ignorance and uncertainty 
(Buckland, 1991). It is therefore ironic that the term information is itself vague and 
used in different ways. The author discusses three different aspects when looking at 
the term information; information as a thing, information as a process and information 
as knowledge 
 
Information has to be represented in a physical way, for example in text, so that it can 
be communicated (Buckland, 1991). Information as a thing can have different forms, 
e.g. text, communication or an object. Therefore information as a thing can impact 
knowledge or communicate information. With information as a process Buckland 
(1991) means that information is an action, to inform or be informed of something. 
When a person is informed the knowledge is forwarded in the process. Buckland calls 
this for information as knowledge. He argues that knowledge is what an individual 
thinks he knows. When an individual is informed the knowledge he possesses 
changes, but not necessarily in the way that he knows more than before. The message 
can be against what we previous thought we knew which can cause bigger 
uncertainty.  
 
Buckland’s view on information is one of many seen in the literature. Additional 
definitions are presented in table 1. Trying to define information in one sentence is too 
much of a simplification. Although some of the definitions in table 1 are similar to 
Buckland’s definition, his view will be used in this thesis because it is comprehensive 
and consistent with the view in this thesis. 
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Author(s) Data  Information  Knowledge 
Wiig - Facts organized to 
describe a situation 
or a condition 
Truths and beliefs, 
perspectives and 
concepts, judgments 
and expectations, 
methodologies and 
know-how 
Nonaka and 
Takeuchi 
- A flow of meaningful 
messages 
 
Commitments and 
beliefs created from 
these messages 
Spek and Spijkervet Not yet interpreted 
symbols 
 
Data with meaning 
 
The ability to assign 
meaning 
Davenport 
 
Simple observations 
 
Data with relevance 
and purpose 
 
Valuable information 
from the human mind
Davenport and 
Prusak 
 
A set of discrete facts 
 
A message meant to 
change the receiver’s 
perception 
 
Experiences, values, 
insights and 
contextual 
information 
Quigley and Debons 
 
Text that does not 
answer questions to a 
particular problem 
 
Text that answers the 
questions who, when, 
what, or where 
Text that answers the 
questions why and 
how 
Choo et al. 
 
Facts and messages Data vested with 
meaning 
 
Justified, true beliefs 
 
Table 1. Definitions of data, information and knowledge (Stenmark, 2002) 
 
2.1.2 Information attributes  
Information attributes have been highlighted in the literature as being important to the 
subject of information valuation (Glazer, 1993; Moody & Walsh, 1999). In contrast to 
more physical products or assets, information can be easily shared between two or 
more parties because it does not follow the principle of either you have it or I have it, 
e.g. a car or a computer. One person can have the exact same information as the other 
at the same time compared to other goods which cannot be accessible to more than 
one person at a time.  Information can be perishable like produce but it’s not 
depletable or scarce as such; in fact information can be seen as self generating where 
the more it is used the more there seems to be. The more information is used the more 
valuable it gets can often be seen as the case (Glazer, 1993). 
 
Partly due to these differences in attributes between other assets and information there 
has been limited success achieved when measuring the exchange value of 
information, although its value in trade or exchange value can be considered to follow 
the economic laws of supply and demand, but the value of information in use within 
an organization has been somewhat elusive.  
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7 laws of information 
An organization has many assets that are of considerable value – information is one 
such asset which has a value based the benefits of its use and the availability. Moody 
and Walsh (1999) have identified a number of general principles which can be used as 
a basis for information valuation. 
 
1. Information is sharable. This means that information can be shared between 
people, organizations and business areas without decreasing in value. This of 
course is an important quality of information, since sharing information is a 
vital part in information intensive companies.  
2. The more information is used, the more value it has. Many resources decrease 
in value when they are used but information exhibits increasing returns to use. 
The cost of information lies in acquiring and maintaining it while the costs of 
using it are almost insignificant. Information that is not used has no value; it 
becomes valuable when it is used.  According to Moody and Walsh (1999) a 
prerequisite for using information effectively is having knowledge of its 
existence, knowing where it is located, having access to it and knowing how to 
use it. According to McGee and Prusak (1993) information must be valued in 
a context of a specific users and decision makers, therefore information is data 
in use where use implies a user. They also state that information is infinitely 
reusable, it does not deteriorate or depreciate and only its user determines its 
value.  
3. Information is consumable. Like many other assets information tends to 
decrease in value over time and according to Moody and Walsh (1999) 
information has three “lives”: an operational shelf life (operational purpose, 
short lifetime), a decision support shelf life (support decision making, long 
lifetime) and a statutory shelf life (for legal requirements, very long lifetime).  
4. The value of information increases with accuracy. The more accurate 
information is the more useful it is to an organization. Inaccurate information 
can on the other hand be very costly to an organization in terms of both 
operational impact and inaccurate decision making. If decision makers know 
how accurate (or inaccurate) the information is they are working with, they 
can incorporate a margin for error into their decisions (Haebich, 1998). 
5. The value of information increases when combined with other information. 
When information can be compared and combined with other information it 
generally becomes more valuable. Being able to relate two sets of information 
together is substantially more valuable from a business viewpoint. Combining 
information is generally necessary when producing decision support 
information because it requires consolidating information from different 
operational systems.  
6. More information is not necessarily better. In many cases the more resources 
you have the better you’re off (e.g. finances). Information is anything but 
limited and the biggest problem in companies today is not the lack there of but 
having easy access to relevant information combined with overload of 
information. Decision making performance decreases once the amount of 
information exceeds a certain point but people still seek more information than 
can be efficiently processed in an effort to avoid mistakes and reduce 
uncertainty. This may lead to the conclusion that people believe that more 
information is better without being aware of their own information processing 
limits. 
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7. Information is not depletable. Most resources are depletable, the more you use 
the less you have. Information however is self-generating, which means that 
the more you use it, the more you have (Glazer, 1993). This is because new 
information is often created as a result of summarizing, analyzing or 
combining different information sources together. The original information 
remains and the derived information is added to the existing asset base and this 
is why information is not a scarce resource.  
 
 
Measurable information attributes 
The value of information is not a function of the information itself, but rather of 
measurable attributes of the information, according to Thomsen (2001). Thomsen 
means that the concept of assigning value to information is a substitute for assigning 
value to the area the information covers. In addition to coverage, the other important 
measurable information attributes are accuracy and timeliness (or speed).  
 
According to Nichols (1987) there are valuable attributes embedded within the nature 
of information which are; relevance, timeliness, availability, comparability, 
objectivity, sensitivity and quality. The relevance of these information attributes is 
based on the reason for its valuation (Poore, 2000). But, for information to possess 
value the first three attributes (relevance, availability and timeliness) need to be 
present but the others can be considered as less important but desirable to some extent 
(Nichols, 1987). Nichols further states that all information, to be valuable, must 
possess quality and mentions validity, accuracy and precision as the most important 
quality attributes.  
 
 
Information quality attributes 
A list of information quality attributes is presented on the Management Information 
Systems Quarterly website [URL1]. Some or all of these attributes (based on the 
reason for the valuation) can be considered relevant when measuring information 
value.  
 
• Currency of information – is the information up to date  
• Frequency of use – how often is the information used 
• Level of aggregation – origination/compatibility of information  
• Relevance of information – how relevant to each situation is the information 
• Source of information – how reliable is the source 
• Information scope – what is the extensiveness of the information  
• Timeliness of information - information provided in sufficient time for an 
action to be accomplished  
• Information structure - how the content is assembled into one unit  
• Age of information – what is the age of information when it becomes available 
to a function or user  
• Reliability of information – how reliable is the information 
• Accuracy of information – the correctness of information  
• Utility of information – what is the usefulness of the information 
• Adequacy of information – how satisfactory is the information 
• Data integrity – how reliable is the source data 
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• Quantity of information – how extensive is the information 
• Recency of information – how recent is the information 
• Value of information – how valuable is the information (strategic value) 
• Information richness – how rich is the information (ex. in content, accuracy, 
timeliness and relevance)  
 
Blumberg and Sparks (1999), mention that the most important information valuation 
criteria are reliability and objectivity of the source of information. 
 
Information as an asset  
According to Moody and Walsh (1999) information satisfies the definition of an asset 
much better than employee or customer, although all three are commonly referred to 
in the literature as intangible assets. Where the company does not own employees and 
customers but information is owned. Information is an intangible asset with relevant 
attributes of having service potential and being able to give economic benefits to its 
owner, but not possessing the physical form of an object. 
 
According to Godfrey et al, Henderson and Peirson (Moody & Walsh, 1999) the 
essential attributes of an asset are: 
 
1. Has a service potential or future economic benefit; something is only an asset 
from an accounting viewpoint if it is expected to provide future services or 
economic benefits. The benefits may arise from either the use or sale of the 
assets. Information satisfies this requirement, because it provides the 
capability to deliver services and to make effective decisions. 
2. Is controlled by the organization; control in this sense means the capacity of 
the organization to benefit from the asset and to deny or regulate the access of 
others to that benefit. Information also satisfies this requirement - if an 
organization has information, it alone has access to it unless it sells or grants 
access to another party. 
3. Is the result of past transactions; this means that control over the asset has 
already been obtained as a result of past transactions such as purchases, 
internal development or discovery. Information also satisfies this requirement. 
Information is usually collected as the by-product of transactions which have 
occurred (internal development), or may be the result of a purchase (e.g. a 
proprietary mailing database) or discovery (e.g. through analysis of data). 
 
2.2 The value of information 
This thesis is to a large extent about the value of information and it is therefore 
important to know how the value term is interpreted when it comes to information. 
This chapter will shed some light on the meaning of the word and how the valuation 
of information can be approached.  
 
2.2.1 What is value  
The meaning of the word value depends on a person’s own perception and can be both 
qualitative and quantitative. Therefore value has various definitions in the literature 
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and Huatuco et al (2001) has identified five main uses and meanings of the term 
value. Therefore the value term is used for:  
 
1. Cost reduction. This is the traditional view when measuring the value of 
information, which is preferable due to the quantitative nature of cost and 
therefore making its measurement objective.  
2. A commodity in the marketplace. Information value is determined upon the 
demand and the supply of the information.  
3. Good decision-making. Information is valuable when it allows good decision 
making and therefore the value is depended upon the quality of the decisions 
made based on the information. 
4. Just in time (JIT). In the JIT perspective the value of information depends on 
its fundamental characteristics, namely; information is delivered to the right 
person, at the right place, at the right time and in the right format  
5. Meeting goals. The value of information contributes when the organization 
wants to improve its performance measures and achieve customer satisfaction.  
 
Hyvärinen and Simpson & Prusak (Huatuco et al., 2001), have recognized the 
difficulty of measuring the value of information. It is only possible to measure the 
effects of value, which suggests that value can only be measured indirectly (Robinson, 
1962). Here, two types of value measurement are defined; indirect and direct.  
 
The indirect type (points 3 and 5) provides the qualitative aspect of the value of 
information. The indirect type is seen as complementary to its direct counterpart. The 
direct type can quantify the value of information in terms of cash units (points 1 and 
2) or in terms of information characteristics (point 4).  
 
2.2.2 Utility value of information  
Information that is useful can be seen as at least as valuable as the use that it is meant 
for (Poore, 2000). Valuing information based on its utility means to a large extent that 
the revenue generation based on the information that is used can be attributed to the 
value of information in part or whole. 
 
Glazer’s (1993) methodology for valuing information assets is based on the role of 
information as a component in the value-add chain. From any given transaction 
between a firm and its customers or suppliers there are valuable information which 
describes the transaction that took place or some related information that can be stored 
within the organizations data repositories. Glazer identifies three components of value 
that can be derived from these transactions, which are: 
 
• Having information about the transaction can aid in future selling/buying of 
complementary products i.e. information can be analyzed for greater benefits 
for the organization. 
• Transaction information can contribute to more efficiency in future 
transactions. 
• The transaction information can have an exchange or market value to a third 
party. 
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In the same fashion the value of the exchange of information within the organization 
can be computed, generally from its contribution to the reduction of production or 
operations cost. According to Glazer, the sum of the information value that can be 
derived from these exchanges of information gives the total information value for the 
organization. The value is enabled to large extent by the inclusion of information 
systems and IT being used within organizations, but keeping in mind that it is the 
information itself that gives the value not the information technology, which is only 
an enabler and therefore assumed to be a fixed cost in the process. As information 
value increases with use the IT cost decreases, which is the assumption of all IT 
investments.  
 
Money Money
GoodsGoods
Information Information
Information
Information
FirmSupplier Consumer
Value of information
from intrafirm
transaction
Value of information
from firm-consumer
transaction
Value of information
from firm-supplier
transaction
Total value of firms
informaiton
 
 
Figure 1: Information valuation procedure (Glazer, 1993) 
 
 
Glazer recognizes how valuing information resources can contribute to the 
information and business strategy and assist in deciding what particular focus and 
commitment to have. 
 
In order to implement the method, Glazer recommends that managers work together 
in order to arrive at a consensus for the value of transaction or exchange data.  He 
further explains that this is necessary in order to make the tacit knowledge that resides 
in the head of managers more explicit. This would help in reducing the overall 
complexity of the valuation problem into a few more manageable problems. Glazer 
identifies the complexity of arriving at a monetary value of information therefore 
states, “the process of going through an information-valuation exercise is sometimes 
as important as the output itself” (p. 106). 
 
One of the key benefits of Glazers methodology is that it can assist companies in 
identifying information that are valuable but not been exploited for its value, therefore 
by going through the process and arriving at a value which could motivate an IT 
investment strategy. The major weakness of this method is that the estimations of the 
value of information are highly subjective and seem to be time consuming to put 
together.  
 
2.2.3 Valuing information based on historical cost 
The historical cost method is a well established and used accounting method that is 
defined as “An accounting principle requiring all financial statement items to be 
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based on original cost” [URL2]. When using the historical cost method the asset (e.g. 
information) is valued based on how much it originally cost to acquire the actual asset 
(e.g. purchase price or development cost). The underlying principle behind this 
method is that the value of the asset is estimated based on the cost at the time of the 
acquisition. According to Moody & Walsh (1999) the assumption is that a firm, under 
normal circumstances, will only spend money to acquire an asset if it believes it will 
receive at least the equivalent amount spent in economic benefits. The historical cost 
method is the traditional cost accounting approach when valuing assets and is still the 
most widely used method in practice despite many attempts trying to replace it due to 
its flaws of not representing the correct market value according to Henderson & 
Peirson (Moody & Walsh, 1999).  
 
When valuing information based on historical cost the information is represented by 
the costs for capturing, producing or purchasing information (Moody & Walsh, 1999). 
The advantage of this method is that costs for collecting information can be quantified 
while benefits tend to be subjective. The disadvantage of the method is that 
undesirable results can be obtained if the historical cost method is used in its standard 
form because it supports the creation of more and more information regardless of how 
(or if) it is used (Moody & Walsh, 1999). They propose several modifications to the 
method, which are: 
 
• The cost of collecting the information should be used as the baseline for 
measurement of value for operational information.  
• The management of information should be valued based on the cost of the 
processes used to extract the information from operational systems. 
• Information that is collected redundantly should have zero value to avoid 
“double counting”. 
• Unused information should be considered to have zero value; this can be 
determined via usage statistics. 
• The value of the information should be multiplied with the number of users 
and number of accesses to the information. When used for the first time, 
information will be valued at cost of acquiring. Each subsequent use will add 
to this value. This means that the historical cost of the information can be 
modified in the light of its use in practice. 
• The value should be depreciated based on the shelf life of the information. 
• The value should be discounted by its accuracy relative to what is considered 
to be acceptable. In practice, this would probably have to be done based on 
perceptions of accuracy, because of the cost of empirically measuring 
accuracy. 
 
By modifying the historical cost method in this way an encouragement is made to 
make existing information available to a larger group of people and users instead of 
simply creating new information. Unused information has no value, just cost. By 
using this approach for valuing information companies can highlight which 
information is most valuable (most used) and which information gives the most 
benefits (cost compared to value). 
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2.3 Increasing the value of information 
Increasing the value of information is an important step for valuing information. In 
this chapter some approaches to increase the value of information will be presented 
and discussed. 
2.3.1 Managing information assets strategically 
Skyrme (1997), in his article on Information Resource Management (IRM), highlights 
some key aspects that need to be focused on in order to manage information assets 
strategically and to fulfill the requirement of having “the right information, in the 
right place, in the right format, at the right time”. Skyrme further recommends that 
organizations should adopt the principles of IRM, typically used for monitoring 
valuable tangible assets, to intangible assets like information because of the increasing 
value of information and lack of management in many organizations.  
 
Some of the more important management aspects that need attention according to 
Skyrme (1997); 
 
• It is important that managers understand the role and impact of information on 
the organization. Whereas information can add value to products and services 
as well as improve quality of decision-making and reduce risks.  
• Establish a clear assignment of responsibility of an organizational wide 
Information Resource Management Initiative (IRM). Because the 
responsibility of developing value from information resources falls often short 
when governance is not apparent. 
• Institute policies for how to utilize information resources throughout its 
lifecycle. Pay attention to ownership, information sharing and integrity. Make 
policies consistent with the organizational culture.  
• Identify information resources, their users, usage and importance. Further 
identify the information cost, value and sources. Classify information by key 
attributes. Classify knowledge and make knowledge maps i.e. inventory over 
what the organization knows. 
• Employ data mining, information refining and knowledge editing 
methodologies and techniques. Using technologies based on intelligent agents 
can help in the data mining process, but topic experts are needed to repackage 
relevant material in a user-friendly format through basic content analysis. 
Refining information methods techniques are examples of commercial 
methodologies that are not widely used by organizations, but can be highly 
valuable. 
• Institute an effective information management strategy through the 
development and implementation of appropriate technological systems. These 
systems can be e.g. intranets, groupware and collaborative technologies for 
more widespread sharing and collaborative use of information as well as 
advanced text retrieval, document and content management and knowledge 
management expertise systems among others.  
• Promote a culture for sharing information through expertise systems and 
communities. 
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2.3.2 Information refining 
While data is mined with the aid of Data Mining (DM) techniques information can be 
said to be refined. That is why beyond data mining, information refining and 
interpretation for corporate wide utilization is what adds value to information [URL3].  
 
According to professor Konsynski (1996) information refining is a computer-based 
process that converts raw information among others, reports, memos, directories and 
databases, into electronic form, extracts the content units and recombines them into a 
new form that can be distributed in a variety of ways. The end product of information 
refining can take several forms and among them a database, marketing report, 
electronic publication, paper publication etc. Therefore the most significant aspect of 
information refining is that it can increase the quality of raw information and in the 
process increases its value by helping simplifying its use for new use and re-use. 
 
Due to the increasing amount of information and its exponential growth, it can in 
many cases be impractical for users to pull useful data from useless information. With 
the aid of computer based technologies that support information refining and business 
intelligence that assist users the value of information can be increased significantly as 
well as information re-use.  
 
Organizations where presented as being information refineries by Clippinger and 
Konsynski (1989) where the information processing infrastructure is represented in a 
well thought out flow. This flow of information has been identified as being 
comprised by the following stages where information refining is the major value 
adding process in the infrastructure; discovery, acquisition, refining, storage/retrieval, 
delivery and presentation/use [URL4]. A closer look at the information refining step 
reveals; standardization, categorization, analysis, integration, interpretation and 
combination that are all value adding attributes (Clippinger and Konsynski, 1989).  
 
A repository of information is created from raw data or information that is discovered, 
acquired and refined before being included in the repository. This refinement process 
can be manual (e.g., keyed in from paper) or computer automated (e.g., standardized 
form, less errors, with indexing and integration with analysis, etc.). A properly 
constructed information repository can be used as a platform for supporting products 
or product families and can allow for continuous discovery of new products with 
lower cost due to the reuse of the information resources. (Zack and Meyer, 1995) 
 
Stokke et.al., (1996) stated that: "Intellectual capital is information that has been 
formalized, captured and refined to produce or manufacture a higher valued industrial 
product" (p.2), further he recognizes information as being the major industrial and 
corporate asset today. 
 
2.3.3 Taxonomy of information 
Taxonomy is a scheme for categorizing and describing different views of information.  
The taxonomy describes the structure, handling, access and intended audience of 
existing information within an organization so it can be accessed, used and reused. 
For an organization to be successful it is essential that it has the ability to collect, 
manage and exploit high quality information. Gaining access to the right information 
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at the right time creates an opportunity for drawing conclusions and making decisions 
that are optimal for the organization. [URL5] 
 
In order to gain access to the right information at the right time it is important to 
increase the value of the information by increasing its accessibility and suitability for 
use and reuse. Skyrme (1994) presents ten aspects that add value to information that 
are presented in table 2.  
 
1. Timeliness Shelf life of information  
2. Accessibility Easy to find and retrieve 
3. Usability Ease of use 
4. Utility Is suited and usable for multiple applications 
5. Quality Accurate, reliable, credible, validated 
6. Customized Filtered, targeted, appropriate style and format 
7. Medium Appropriate for portability and ongoing use 
8. Repackaging Reformatted to match onward use 
9. Flexibility Easy to process (can be used in different ways) 
10. Reusability Can be reused 
 
Table 2: Ten aspects that add value to information, (Skyrme, 1994) 
 
The aspects presented in the table refer to increasing the user experience and 
usefulness of the information needed. These ten aspects are consistent with various 
information quality frameworks as well as information refining methods and 
taxonomy procedures that can increase information value through e.g. reuse. 
 
Information can be found in different areas of an organization’s environment; in 
different databases, formats and physical locations. It is a big assignment for an 
organization to gather, collect and reuse this information and it requires an enterprise 
wide plan to describe, manage and distribute the information and the information 
environment. This means that companies must analyze and build an information 
infrastructure that represent full value of information. Full value is experienced when 
the information consumer can get consistent, updated and correct information 
concerning their business domain, at the right time. The way information is accessed, 
used and presented must be taken into account when the taxonomy is created. [URL5] 
 
Many companies are surprised to see to what extent a taxonomy analysis is actually a 
business analysis. Since taxonomy is created in order to describe information so that 
the information can be utilized and acted upon it must reflect the business needs of the 
organization. In the end the design and development of the taxonomy should be done 
with the aim of meeting these specific business needs. [URL5] 
 
2.4 Risk  
Risk is an extensive subject area covering several organizational areas, e.g. insurance, 
legal, financial and information management (security risk). The purpose of this 
chapter is not to cover risk through its extensive organizational impact e.g. drug 
development and clinical research but rather define the concept of risk and set the 
stage for its narrow scope presented in this thesis, which is highlighting risk elements 
that can affect information value. 
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2.4.1 What is risk  
 
• Risk is – “the chance or likelihood of an undesirable event occurring and 
causing loss or harm. The key element of risk is uncertainty, without which, 
there is no risk”.  
• Risk Analysis is – “the process of gathering and analyzing risk-related 
information in the preparation of a risk assessment”. 
• Risk Assessment is – “a detailed articulation of the risks associated with the 
information assets and supporting Information Technology and 
communication (IT&C) resources at risk, threats that could adversely impact 
those assets and vulnerabilities that could allow those threats to occur with 
greater frequency or impact”. 
 
Ozier, (2003) 
 
Risk management is defined by Caelli et al. (Finne, 2000) as having the aim of 
protecting an organization from incurring financial harm by “identifying, measuring 
and controlling uncertain events” at the lowest possible cost to the organization. Blake 
(2003) means that risk can be divided into basically two types, pure - and speculative 
risk.  
 
• Pure risk: where loss is certain 
• Speculative risk: the degree of loss varies 
 
Further Blake explains that these risks usually take the form of some or all of the 
following: 
 
• Economical (market changes)  
• Legal (liability)  
• Social (public relations) 
• Political (government interpretations) 
• Juridical (jury decisions) 
• Physical (property)  
 
Risk management issues are not stationary by its nature with constantly changing 
circumstances, both inside and outside of the organization, forces organizations to 
look at risk from a broad spectrum. The trend to look at risk management with this 
broad perspective has proved necessary since organizations are constantly exposed to 
risks that can be both pure and speculative (Blake, 2003). 
 
2.4.2  Valuing information from a risk management perspective 
Valuing information can prove useful when making decision on investment in 
technology for risk evasion. Having a balanced view of the cost of information control 
and the information value from a risk management perspective is the main message of 
the valuation methodology presented by Poore (2000).  
 
Gunnar Gunnarsson & Jökull M. Steinarsson  Approaching Information Valuation 
 18 
 
Poore mentions that valuing information depends to a large extent on the purpose of 
the valuation therefore as such information can have several values. The author rejects 
the cost based valuation method as well as other methods relying solely on subjective 
opinions because they do not consider the risk management perspectives. Valuing 
information from a risk perspective differs from other valuation methodologies in 
Poore´s view where one or more of the following conditions are most likely the 
motivating factors for the valuation: 
 
• Exclusive possession - Having exclusive possession of some information can 
be valuable for an organization. If the information is no longer exclusive then 
its value is diminished and if the organization is not aware of the loss of 
exclusivity it can lead to potential risk. 
• Utility - Useful information can be seen as having a minimum value of the use 
it relates to in the organization.  At the same time having information that 
cannot be used to its full potential can have negative value (maintenance cost, 
liability etc.).  
• Cost of creation or re-creation - Valuation is based on how much it did cost 
the organization to acquire the information. From a risk management 
perspective if the information can be re-attainable for approximately the same 
cost the valuation can be useful. However if the process for recreating the 
information cannot be repeated then this valuation is not useful. If it is known 
that the recreation of the information is possible but for a higher cost that 
valuation could prove to be more relevant.  
• Liability - Organizations may have liability concerns associated with 
information, for example be liable according to law, safety or third party 
interest. The organization may choose to value the information according to 
the ramification if a trust is breached. Poore means that liability issues can 
arise from issues of confidentiality, availability or integrity. Recognizing the 
difficulty in making a forward looking or hypothetical case resulting in 
liability damages, Poore suggests this valuation principle should best be used 
based on a historical case or previous occurrences.  
• Convertibility - When information is representative for value, that is 
convertible to other assets, the information should be valued to at least the 
conversion value. The information value should be derived from the security 
risk assessment for unauthorized use or change to the information, which 
could occur and be undetected or unrecoverable.   
• Operational impact - Information valuation can be based on the impact the 
absence of the information and/or data could have on the organization. If a 
timely access to pertinent and correct information is not available how would 
that affect the operations? Therefore quantifying the impact can give the value 
of information from a risk management perspective.  
 
 
Quantifying information assets 
If information is accurate, timely, permitted, useful and rare it can be seen to have a 
positive value and if the contrary is true it can be a liability, meaning having a 
negative value. Poore suggests that the value of information from a risk management 
perspective can be presented on an interval where the scale of positive (value) and 
negative (liability) information value would represent the total value of the 
information to the organization.  
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-1 43210-6 -5 -4 -2-3 65
1 = $100.000
Total value = 8
 
Figure 2: Value to the organization, (Poore, 2000) 
  
Example: If the information value is 3 and the liability related to the same information 
is -5 then the total value of the information to the organization is 8. 
 
Information valuation techniques 
As mentioned before different techniques for valuing information are required in 
different situations all depending on the source of value the information has to the 
organization. Poore provides short examples of techniques for valuing information 
assets, but not in any detail. As a reference for further exploration of techniques for 
valuing information assets, Poore suggests a publication from the Information 
Systems Security Association (ISSA) called Guidelines for information valuation 
published in 1993. (The authors of this thesis where unable to obtain a copy of the 
document which is under revision, planned to be republished in the first quarter of 
2004)   
 
Multidimensional value of information 
According to Poore the aforementioned categories of information valuations can be 
viewed as multidimensional in the sense that they can be affected independently by 
security elements such as confidentiality, reliability and availability. The affects the 
security elements have on the information valuation are mapped in table 3. Poore 
suggests that when performing the valuation the focus should be on the security 
elements most directly affecting the purpose of the valuation and a special attention 
should be on how they are categorized and dealt with for risk evasion. 
 
 
Sec. element 
Inf. value 
Confidentiality Availability Integrity 
Exclusive possession x   
Utility  x  
Original cost or cost of 
re-creation 
  x 
Potential liability x x x 
Convertibility x x x 
Operational impact  x x 
 
Table 3: Multidimensional information valuation, (Poore, 2000) 
 
Gunnar Gunnarsson & Jökull M. Steinarsson  Approaching Information Valuation 
 20 
 
• Confidentiality: information being secret or private within a predetermined 
group. Sensitive information is protected from unauthorized or premature 
disclosure.  
• Availability: information being accessible and usable within a reasonable time 
when it is required by the administrative organization. 
• Integrity / quality: information being correct and sound representation of 
authorized administrative and business processes. 
 
(Finne, 2000) 
 
Qualitative value of information 
Poore gives examples of qualitative valuation of information when a quantitative 
valuation is not practical. He recommends a rank ordering of risk valuations that have 
been identified through a risk assessment process. A simple rank ordering from least 
to most damaging risk is suggested since the process of going through the risk 
assessment provides management with sufficient information for informed decision 
making.  
 
2.5 Conclusion  
The conclusion from the information as a concept chapter is that the value of 
information is more difficult to measure than other assets, which can to some extent 
be related to the difference in their attributes. One of which is the fact that information 
can be indefinitely shared between two or more parties at the same time unlike e.g. 
car, computer and factory. Information value increases with use, accuracy and the 
more accessible it is to users. Therefore, information can be valued with regards to 
information attributes like accuracy, timeliness, content etc., which are closely related 
to information quality aiming to increase the availability and usefulness of the 
information. 
 
The conclusions drawn from the value of information chapter is that the meaning of 
the word value usually depends on a persons own perception which can be expressed 
both qualitatively and quantitatively and that a value can only be measured by its 
benefits e.g. cost reduction, decision making, commodity in the marketplace. 
Therefore information can be viewed to be at least as valuable as the use it is put to. 
Two perspectives for valuing information are presented in this chapter, utility value 
and historical cost value. With utility value information can be seen as a component in 
the value-add chain, which means that the value can be related to a revenue-
generating product. The historical cost method is based on the accounting principle of 
basing the value of information on the cost of its acquisition, but adjusted through 
several aspects that are constantly being monitored throughout the information life 
cycle e.g. use, shelf life and accuracy.  
 
In order to realize the full benefits of information assets it has to be managed 
strategically which is the main conclusion from the increasing the value of 
information chapter, in addition the infrastructure should promote the availability of 
the right information, at the right place, at the right time. This can be done by 
identifying various information resources and their users, gather, collect and reuse 
information by employing information refining and taxonomy as well as promote a 
culture for sharing information.  
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Risk management is about defending an organization from unknown events that can 
lead to financial harm. A conclusion drawn from the Risk chapter is that general 
operational risk like economical, legal, social and political are relevant to the 
pharmaceutical industry and can be related to information resources through several 
risk factors. Based on this it is therefore possible to focus on valuing information from 
a risk management perspective and based on the reason and the purpose of the 
valuation information can have several different values either quantitative or 
qualitative.  
 
The methods for valuing information in the literature review where chosen due to 
their different qualities and contribution to approaching the concept of valuing 
information, they are; utility value method, historical cost method and valuing 
information from a risk management perspective. Although, these methods represent 
to a varying degree a usable method they pertain several usable aspects that can be 
adapted and used in analyzing the subject at hand. Table 4 highlights some differences 
in the approaches and how they can be used. 
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Historical cost method, 
Glazer, Moody & Walsh. 
Utility value method, 
Glazer. 
Information value from a 
risk management 
perspective, Poore. 
Use: The value is based on 
the cost for acquiring the 
information at the time of the 
acquisition and adjusted 
through several aspects that 
are constantly being 
monitored throughout the 
information life cycle e.g. 
use, shelf life and accuracy.  
 
Advantage: Objective and 
quantifies a value. 
Theoretically this method 
can be used to highlight 
which information gives a 
good ROI. Contains usable 
definitions of information as 
a concept. 
 
Disadvantage: Difficult to 
implement, requiring special 
IT/IS infrastructure to 
monitor use. May not reflect 
the correct value since the 
value is based on the cost at 
the time of the acquisition.  
 
Use: Information value is 
based on the benefits gained 
from having the information. 
Revenues that can be 
associated with the 
information is used to base a 
value. Can be used to 
measure increased revenues 
or decreased cost as a result 
for having information. 
Information not the 
technology gives the value 
which can be used to decide 
on what particular focus and 
commitment to have in the 
IT/IS strategy.  
 
Advantage: Identifies 
information that is valuable 
but not exploited for its 
value. Promotes focusing on 
information rather than on 
technology.  
 
Disadvantage: Value based 
on a subjective view, focus 
on revenue contribution 
which generally can be 
difficult to accurately 
correlate with a product. 
 
Use: Organizations should 
value information based on 
the reasons for the valuation, 
which can give different 
valuation, accounting for 
various information risk 
aspects. Can be used to 
decide on what particular 
focus and commitment to 
have in the IT/IS strategy. 
 
Advantage: Considers risk 
aspects that can contribute to 
information value, gives 
examples on the quantifying 
and qualifying value concept. 
Identifies information value 
as multidimensional.  
 
Disadvantage: Not 
conclusive in demonstrating 
an information valuation 
procedure. Valuation is 
subjective based on previous 
knowledge and experience. 
Gives several values which 
can be difficult to interpret 
and be misleading.  
 
 
Table 4: Overview of the valuation methods presented 
 
The overall conclusion is that the methods analyzed in the literature review are by far 
flawless and not problem free to implement. Although, the most appropriate approach 
to the question at issue is believed to be based on Poore’s method. The method 
demonstrates understandable associations between several risk aspects and 
information value that can be applicable although several modifications are necessary 
in order to represent a proper focus on the problem at hand.  
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3 Method 
In this chapter the differences between qualitative and quantitative methods are 
discussed followed by a discussion of possible methods for collecting information that 
are relevant to this thesis. The chapter argues for the chosen methods that are used in 
addition to describing the work process for the literature and the case studies. The 
chapter concludes with a discussion on how to deal with uncertainties.  
 
3.1 Type of examination 
There are, according to Patel & Davidsson (1994), two different ways to work up 
collected information, which are qualitative and quantitative. Even if the type of 
examination mainly depends on the way collected information is treated, it is here 
considered important that this is clear from the beginning and therefore the whole 
examination process will be characterized by this choice. Below, the difference 
between qualitative and quantitative examination will be explained and at the same 
time the discussion will be linked to this study.  
 
According to Patel & Davidsson (1994), quantitative information processing is built 
on statistical methods where the results from a research are described in numbers, 
graphs or tables or as a hypothesis where statistics are used to test statistical 
hypothesis. The purpose of qualitative investigations is to gather different and deeper 
knowledge compared to when using a quantitative methods. Quantitative observations 
strive to understand and analyze the entirety. Because qualitative measures often build 
on interpretation from text based material, the results can get characterized by the 
person that performs the observation more easily than with quantitative observations. 
The authors argue that it can be practical to do ongoing analysis in qualitative 
observations.  To do an analyzes directly after an interview or an observation can give 
ideas on how the work can go on and at the same time it is always good to analyze the 
material while it is still fresh in the mind. 
 
This study will use a qualitative approach since the purpose is not to give statistical 
answers on a number of concrete questions but to describe the situation using 
publicized material and by conducting interviews. The analysis will therefore mostly 
be in the form of text and model built on the authors interpretations of the material 
investigated in this thesis.  
 
3.2 Possible methods for collecting data/information 
In many cases various methods can be used for solving a problem. It is hard to say 
that a certain method is better or worse than anyone else, it depends first and foremost 
on the problem at hand which method to apply. When applying a method for solving a 
problem it is important to consider the time and means available for solving the 
problem. When choosing a method it is important to find out what techniques are to 
be used for collecting the information and which individuals will participate. (Patel & 
Davidson, 1994) 
 
Based on this works problem specification various methods could be used to solve the 
problem, therefore the methods used in this thesis are:  
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• Literature studies 
• Interviews  
• Case studies 
 
These methods will be described in the following subchapters along with their 
advantages, disadvantages and their relevance to the study.  
 
3.2.1 Literature studies  
Patel & Davidsson (1994) categorize literature studies as document studies along with 
studies of other various document types like statistics and register, government and 
private documents and documents with picture and sound. According to this, movies, 
fiction and technical literature can be classified as literature. The authors point out 
that it is important to choose literature that gives as complete picture as possible so 
that the problem can be seen and analyzed from many angles. A common trap to fall 
into is to only use sources of information that back up the researchers own ideas and 
opinions. It can be problematic though to use different sources since the credibility 
and quality can be compromised. It then becomes important to view the material from 
a critical point of view – that is the perception of the quality of the literature. It is 
important to ask questions about the authors’ authority, the purpose of the text in 
addition to how, when and where was it published. Texts are often transformed 
through people’s interpretations and therefore it is crucial to assess if the source is 
primary or secondary. 
 
The benefit of literature studies is that the researcher can often control the 
examination in accordance to time and place. Literature studies can give a broad and 
scientifically recognized knowledge about the area of research and are often in some 
form necessary in context with other types of studies. The disadvantages with 
literature studies are that it can often be difficult to establish a real life connection to 
the thing being studied as well as that it can take a long time to get full knowledge of 
the research area.  
 
It is important to build a theoretical picture of the research area in a study like this and 
therefore the literature study is conducted early with a purpose to use as a guide for 
the interviews. 
 
3.2.2 Interviews  
The interview techniques are based on asking questions to individuals or groups and 
document the answers. Interviews can be made in many different ways, but the form 
used in this thesis is personal interviews. According to Patel & Davidsson (1994) 
there are two main aspects that must be considered when information is gathered 
through interviews: a degree of standardization and a degree of structure. The degree 
of standardization is about how prepared the questions are and what their rank is 
before the interview. If the degree of standardization is low the questions are 
formulated during the interview and asked in the order that is appropriate each time. A 
high degree of standardization means well prepared questions asked to all the 
interviewees in the same order. That type of interview is often used for comparison 
and generalization. The degree of structure is about what kind of freedom the 
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interviewee gets in his/her answers. A low degree of structure means open questions, 
which the interviewee can answer freely to, while a high degree of structured 
interviews leaves little room for indirect answers. The answers are more predictable 
and easier to compare between different interviews with a high degree of structure. 
 
The benefit with interviews compared to other techniques is that they can be very goal 
oriented and therefore give a high qualitative result if the right person is interviewed 
in the right way. The interviewer can also affect and stimulate the respondent and 
explain the questions and their meanings if that is necessary. The respondent can at 
the same time explain his/her answers and perhaps clarify them with the help of 
pictures, graphs, body language, etc. In this way interviews can give a better view of 
reality that e.g. literature studies. The disadvantage with interviews is that they can be 
time consuming in both preparation and realization. It is vital to get hold of the right 
persons; they can be uninterested, busy or be in a place that is geographically far 
away. Another possible risk is that the interviewer affects the respondent in a way that 
is favorable to the interviewer and therefore the wrong measure can be made.  
 
The interviews are important since the academic literature within this thesis research 
area is insufficient in some way and the area as such is relatively young and 
unexplored. 
 
3.2.3 Case studies 
The method case study is, according to Svenning (1997) a study of intensive character 
that can be conducted over a short or a long period of time. The method means that 
the person conducting the study gathers material about one or several cases through 
e.g. interviews or observations. According to Patel & Davidsson (1994) case studies 
are conducted on a small group that can be represented by individuals, organizations 
or situations. When conducting a case study a broad perspective is assumed with the 
aim of getting information that covers as much as possible. According to Svenning 
(1997) the case study gives a clear and detailed picture that can be the cornerstone for 
generalizations. The disadvantage with one case is that it can get to specific for others 
to benefit from the lessons learned in the case while many or several cases often don’t 
give a deep understanding of a problem. In order to collect the desired information for 
the case studies interviews will be used.  
 
3.3 Approach 
This section presents how the methods, from the previous chapter, where used in 
order to solve the problem statement. First an introduction on how the problem area 
was chosen will be presented and thereafter the literature study and the empirical 
study including the interviews will be outlined.  
 
3.3.1 Introductory discussion 
In order to decide the problem area of interest for this thesis the authors participated in 
a BizNet1 meeting where representatives from Volvo, SKF, AstraZeneca, IT 
                                                 
1 A network of organizations and researchers at Victoria Institute, with interest within the area of 
Business technology. 
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University and Viktoria Institute were present. After that meeting a contact with 
AstraZeneca was established and a basis for the research area was reached. This was 
done through several discussions with Kerstin Forsberg (Medical Informatics) and 
Elof Dimenäs (Medical Informatics) at AstraZeneca in Mölndal. This resulted in an 
area of interest being chosen, which was appealing to investigate further in a form of a 
masters thesis. During the work on the thesis the question at issue changed a number 
of times as the problem area became more apparent. 
 
3.3.2 Literature study 
It is important to read already published material within the research area before the 
work can begin (Patel & Davidsson, 1994). This was helpful in order to get a broader 
understanding within the research area, which in turn made the study easier to 
conduct. The aim of the literature study was to build up a background for the thesis 
and to get a wider understanding about the area of interest. The literature study 
conducted during the course of this work can be categorized into four groups; books, 
articles, documents and Internet material.  
 
Books: Books are a good way to obtain recognized theories within a research area. 
Since valuing information is a relatively new subject is was difficult to find up to date 
books that cover this subject, relevant to the scope of this thesis. The books used have 
been obtained through Handelsbiblioteket at Göteborg University and the library at 
AstraZeneca. 
 
Articles: Articles can provide up to date information about a certain research area to a 
bigger extent than books, which was most helpful during the course of this work. The 
articles used have been obtained through online electronic databases at 
Handelsbiblioteket at Göteborg University, the library at AstraZeneca and through the 
Internet. 
 
Documents: While working on the Losec, Plendil and Exanta cases internal 
documents in the form of reports, articles, presentations and internal memos were 
reviewed. These documents were acquired through the projects supervisors at 
AstraZeneca, the persons interviewed and the company’s Intranet.  
 
Internet material: A great deal of information used in this work has been acquired on 
the Internet. Most of this information has been in the form of articles but even 
company information. The Bayer Baycol case is entirely built on information from 
medical databases, news related sources and Bayer’s website.  
 
3.3.3 Case study 
The case study included four cases, three concerning AstraZeneca and one concerning 
the pharmaceutical division of Bayer AG. The information for the AstraZeneca cases 
was obtained though interviews with individuals at AstraZeneca in Mölndal and from 
the company’s intranet, while the information for the Bayer case is solely based on 
information from medical databases, news related sources and the company’s website.  
 
 
 
Gunnar Gunnarsson & Jökull M. Steinarsson  Approaching Information Valuation 
 27 
 
Interviews  
In the case studies three cases were examined and interviews were held with key 
individuals in each case. The interviewees were divided into two groups depending on 
their role in the case: a technical role and a business role. In the Losec case there were 
three interviewed held, two in the Plendil case and one official interview in the Exanta 
case. The respondents roles in each case are shown in table 5. 
 
The interviews had more the character of a discussion where the questions were open 
and the respondents answered freely about their roles in the cases and how they 
played out in their view. Nevertheless several questions had been constructed 
beforehand as a basis for the interviews. Each interview was recorded on tape and 
after each interview transcripts were made based on these recordings. The transcripts 
where then send to the respondents for additional comment and validation.  
 
 
Case Role 
Losec case: Technical: Two persons where interviewed; one was the driving force in 
building the safety database and one who was responsible for retrieving the 
information from the safety database.  
 
Business: One person interviewed who was a key person representing the 
company in this case. 
Plendil case: Technical: One person interviewed who was a key persons in retrieving and 
compiling information for this case. 
 
Business: One person interviewed who was working with international 
marketing and involved with information sharing in this case. 
Exanta case:  Technical: One person interviewed who worked on a proof of concept for the 
project as well as being a information architect for the consolidated clinical 
data storage (CCDS). 
 
Business: discussions held (not a formal interview) with a key person 
working on the business case for CCDS.   
 
Table 5: Interviewees and their role 
 
In addition to these interviews, discussions were held with the projects supervisors at 
AstraZeneca which gave valuable input to all the cases.   
 
3.3.4 Dealing with uncertainties 
It is important in every examination to value the validity of the study. According to 
Patel & Davidsson (1994) this means measuring the validity and the reliability of the 
study. Validity has to do with the concurrency between the subject being studied and 
what really was studied. A qualitative study like this one is about studying abstract 
concepts like value and information, which means that it is difficult by certainty to 
identify how the methods used, can generate answers to the questions asked. In this 
study the question about validity is about whether the questions used in the interviews 
fills it purpose. This so-called interview validity has in this study been accomplished 
through an analysis of the questions along with the project supervisors at AstraZeneca 
and therefore the questions are believed to have a fairly good validity. Another 
uncertainty concerning the validity is the number of interviews conducted and the fact 
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that two of the cases occurred ten years ago. Despite this, it is believed that the 
validity of the respondents and the material is valid since these persons where 
carefully chosen by the project supervisors. Additionally, the studies have benefited 
from having access to internal documentation relevant in each case.  
 
According to Patel & Davidsson (1994) reliability is about how well the instruments 
used can resist different types of randomness. The results of interviews always contain 
an uncertainty factor that can depend on various things, e.g. the interviewer’s ability 
to register and assess the respondent’s answers can be defective. The prerequisite for a 
good validity is thus that the interviewer is well trained or that the interview is 
structured in a way that the answers don’t need interpretation from the interviewer. 
Another factor that can affect the validity is the so-called interview effect. This is 
about how the interviewer can influence the respondent and help them to understand, 
aware or unaware, what is expected of them. The authors of this thesis have previous 
experience of using the techniques used in this study to conduct interviews and 
therefore the reliability has been increased due to this fact. Also the questions used are 
believed to be at such comprehensive level that the knowledge possessed by both 
interviewers and respondents within the research area is of great advantage when 
analyzing the material. Furthermore all interviews have been recorded, which gives 
the possibility to listen to the answers repeatedly and thus increase the quality of the 
interpretation. To sum up the credibility of this study is believed to be acceptable for a 
study of this size and within the research area.  
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4 Empirical study 
The chapter begins with a short presentation of AstraZeneca as a company followed 
by a description of the medical informatics department at which the work on this 
thesis took place. Thereafter the case studies are presented and their key finding. 
 
4.1 AstraZeneca company information 
AstraZeneca is one of the world’s leading pharmaceutical companies. The company’s 
core competence lies within the areas of discovery, development and marketing of 
innovative pharmaceuticals for treatment of deceases in areas of important medical 
needs.  
 
The company provides innovative medicines designed to fight disease in important 
medical areas like: cancer, cardiovascular, gastrointestinal, infection, neuroscience 
and respiratory [URL6]. The company is concentrated on seven important areas of 
decease: heart/vessel, stomach/intestine, cancer, alleviation of pain, central nervous 
system, respiratory systems and infections [URL7].  
 
AstraZeneca’s headquarters are located in London, while research and development is 
led from Södertelje, Sweden, in addition to having a strong presence in USA. 
AstraZeneca operates sales offices in over 100 countries, production in 20 countries 
and employs approximately 58.000 people of which 11.000 are located in Sweden. 
Total sales for the year 2002 were $17.8 billion. [URL7] 
 
4.1.1 AstraZeneca R&D in Mölndal 
AstraZeneca’s site in Mölndal is one of the company’s larger research centers. 
Approximately 2,300 people are employed there for research and development of 
cardiovascular and gastrointestinal medicines. [URL8] 
 
The company’s research in Mölndal has contributed to the production of a number of 
medicines. Omeprazol, which has been marketed under the name of Losec (Prilosec), 
has been the most successful to date. The follow-up to Losec, Nexium, was developed 
in Mölndal and was introduced to the market in the autumn of 2000. Researchers at 
Mölndal are also working on several interesting projects within cardiovascular 
medicine, such as, thrombosis inhibitors (Crestor) that will prevent the occurrence of 
blood clots and Exanta the first oral direct thrombin inhibitor. [URL8] 
 
AstraZeneca R&D Mölndal is a complete research centre that covers the range of pre 
clinical, pharmaceutical and clinical trials and contact with authorities. Some hundred 
co-workers are involved in the global marketing of medicines that are developed at 
Mölndal. [URL8] 
 
Medical Informatics 
This thesis was done at the medical informatics department, which is a part of Clinical 
Science. The main goal of medical informatics is to implement strategic directions 
and create an environment that allows efficient access to all relevant internal and 
external scientific information. Its role is also to establish an information structure 
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within the company and motivate the organization to share, exploit and explore 
scientific information as well as increase personal networking across the organization.  
 
4.2 Case introduction 
The cases in this study were chosen due to their significance to AstraZeneca and in 
the Bayer case to the pharmaceutical industry as a whole. These cases portray the use 
of information or a lack thereof, supporting the value of information promoting 
accessibility of organizations information resources. The first three cases are 
presented to illustrate how valuable Clinical Research (CR) information are to 
pharmaceutical organizations and the role information plays in resolving possible 
adversities (issues) that occur to medicine. In addition a fourth case presents 
AstraZeneca’s current information environment and a proposed future information 
environment. The Losec, Plendil and Baycol cases are given in order to highlight the 
importance of developing an information environment that promotes risk evasion in a 
proactive way, case in point the consolidated clinical data storage (CCDS) presented 
in the Exanta case.  
 
4.2.1 Case overview 
The first two cases (Losec and Plendil) are internal cases from AstraZeneca that 
capture in retrospect how issues where handled, at the time of Astra-Hässle and how 
the information infrastructure supported the resolution of issues. The cases highlight 
the technical and administrative initiatives put in place in order to resolve the issues as 
well as what effects they had on the organization and its markets.  
 
The Losec case describes the occurrence of adverse events reported in Germany that 
brought on an intensive investigation by the authorities. The Losec case can be 
viewed as an example of successful issue handling and proactive thinking in 
constructing a information environment for CR information for defense purposes.  
 
The medicine Plendil was questioned in context to its medical class and was 
implicated to several severe adverse events that occurred. The case can to some extent 
be viewed as less successful because of how costly and time consuming its resolution 
became, mainly due to the lack of information availability and usability.  
 
The third case can be seen as a worst-case scenario and is based on the German 
company Bayer with its cholesterol lowering medicine, Baycol. The purpose of this 
case is to capture in retrospect the extremities of the situation that occurred when the 
drug was linked to patient’s deaths and how the case played out. The economic 
ramifications to Bayer will be addressed and the case will seek to identify risks and 
their extreme consequences. Furthermore the aim is to establish what went wrong and 
if it could have been handled any differently from an information value perspective. 
This case can be viewed as a non-successful example of information management due 
to the ramification it had on the company as well as the pharmaceutical industry as a 
whole.  
 
To get a current and future view on how issues are handled at AstraZeneca the fourth 
case presents in general terms how the information environment at AstraZeneca 
supports handling of issues and how well this environment can support handling of 
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future issues. This case will highlight and compare the differences between current 
and earlier information management environments at AstraZeneca as well as the 
business case for CCDS. The focus will be on risk management perspectives as well 
as the cost and benefits of a new information environment.  
 
4.2.2 Key findings 
At the end of each case key findings will be presented, highlighting the main points 
that form the basis for the analysis chapter. Thereafter, several what if questions that 
arose within the interviews are offered for consideration. 
   
4.3 Case 1: Losec (omeprazol) 
 
Key facts: 
Losec (omeprazol) was first launched in 1988 and works by blocking the final step in 
the production of acid in the stomach, allowing any damage in the stomach, caused by 
excess acid, to heal. The medicine became the global standard in treatment of patients 
with acid-related disorders. In 1998 sales of Losec reached the $5 billion milestone, 
the world’s biggest ever selling branded pharmaceutical and in the year 2002 its 
revenues were $4.6 billion. Today, Losec is a part of AstraZeneca family of mature 
brands and its revenues have provided the basis for the company’s success. Patents 
protecting Losec expire in all major markets between 1999 and 2004.  
 
 
Background  
In July 1993 a German Consumer Drug Journal published a short notice that implied 
that omeprazole caused visual disturbances and blindness. The grounds for this were 
two cases of visual disturbances in severely ill patients that had gone through 
extensive medical treatments that included Losec and up to 25 other medications. 
Astra had received information about the two cases, informing the German authorities 
in addition to visiting the clinics where the patients where. Later that month a notice 
with similar content was published in the official Journal of the German Health 
Authorities (BGA) and also in “Pharmazeutische Zeitung”. Both journals reported 
similar cases receiving considerable public attention as well as being picked up by 
other popular media.  
 
In October 1993, Astra concluded in a report to the BGA that the symptoms observed 
were related to the patients’ severe diseases and not the omeprazole treatment. This 
report included statements from experts as well as results from toxicological studies.  
 
In March 1994, Astra Germany received a letter from the BGA, demanding 
modification to the instructions that came with the medicine. It was also suggested 
that the injection form of omeprazole (not the infusion form which also was available 
in Germany) should be taken off the marked and that Astra was to conduct a 
considerable amount of additional animal and human studies. Supporting their 
arguments BGA referred to a total of 16 reported cases from Germany, two from 
USA, one from UK concerning symptoms of reduced eyesight and blindness as well 
as reference to four cases of weakening or loss of hearing.  
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In March 1994, Astra sent a response to the BGA where it was explained that the 
results of careful evaluation of all available pre clinical and clinical information 
including some animal studies utilizing the most up to date technique available 
showed no evidence that suggested causal relationship between omeprazole and the 
claims made by the BGA. The response included a large number of supporting 
materials from independent international experts and opinion leaders within e.g. 
toxicology, internal medicine and ophthalmology (eye care physicians). 
 
During the spring of 1994, the BGA/omeprazole issue was repeatedly brought up 
within CPMP (Committee for Proprietary Medicinal Products) the committee dealing 
with pharmaceutical products within the European Union. At a CPMP meeting in July 
1994, BGA delivered a report demanding handling of the issue within the CPMP 
before the end of July. Astra was invited to a hearing at this extra meeting in July. 
Five external experts and three experts from Astra, represented Astra. The result from 
the meting was an official statement, which concluded that a fundamental association 
between the reported symptoms and the use of omeprazole was not established.  
 
 
July 1993: the
first indication
that omeprazol
caused blindness.
Oct. 1993: Astra's first
response, the symptoms
cannot be related to the
omeprazol treatment.
March 1994: German authorities
demand modifications to the
medicine instructions and the
injection form should be taken
off the market. Astra responds
that there is no connection to
blindness and omeprazol.
July 1994: CPMP receives a
report from BGA demanding
handling of the issue. At a
meeting later that month Astra
was cleared of all allegations.
JanDecNovOctSepAguJul JulJunMayAprFeb Mar
199419931988
1988: Losec
(omeprazol) first
marketed
 
Figure 3: Timeline in the Losec case 
 
 
Internal view 
When the issue came up Astra quickly realized that it had to be dealt with. The Losec 
issue became almost an own organization with special funding and a management 
strategy team led by the vice president of the company. An executive team was built 
that included doctors, administrators, the chief of marketing and the chief of 
regulatory affairs. This made the decision making process very short. Later on when 
things got even more serious and the pressure of proving that Losec had nothing to do 
with the allegations a small organization was built to handle the issue, which included 
teams of scientists, regulatory affairs, legal affairs, IT/IS, strategic and crisis 
management people. These teams were based on current organization within Astra 
Hässle at that time, which made things easier.  
 
From the very beginning Astra decided not to keep any information from the German 
authorities, they were to get all the information they needed. Astra provided them with 
enormous amounts of information, a total of seven thousand pages that included 
documentation from 75 million oral treatments, 4.5 million intra venous treatments, 
177 pharmacological studies and 35 thousand patients (each with its own “record”) 
from clinical studies. All this information was provided in three week in addition to 
the various additional studies made. One such study was a study made on rabbits in 
Los Angeles in order to determine if Losec caused eye problems. Six of the biggest 
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experts within the field of neurological eye decease where also involved in viewing 
the material.    
 
The information environment 
The information needed in this case was stored in two databases, the safety database 
and the corresponding medicine database (in this case Losec). The data stored in the 
safety database included all information about marketed products that Astra Mölndal 
was responsible for including all substances that were relevant in clinical trials that 
Astra Mölndal was responsible for: 
 
• Central clinical data and information on all patients 
• Local clinical data and information concerning patients with SAE 
• Post marketing surveillance, (from e.g. health professionals, authorities, 
literature) including reported adverse events/adverse drug reactions.  
 
The safety database contained pulled data and information needed but clinical data per 
study was in the Losec medicine database, which was not pulled and therefore not 
ready for use in this case. The safety database proved an invaluable resource, since the 
Losec medical database was build to fulfill government regulations not for scientific 
purpose and therefore difficult to pull from.  
 
The safety database was build for scientific use and the data could therefore easily be 
pulled. The database was build so that trends and side effects could be identified early 
on, which now can be seen as a very proactive thinking. All safety data was available 
since 8 years back. Individuals at the safety department knew that it was going to be a 
substantial requirement for quick access to information and data, especially safety 
data, for defending popular medicine. In the market there was fierce competition 
between pharmaceutical companies where positive effects of the drugs were not 
highlighted only the side effects.  
 
Therefore, because of the information environment where the information was 
structured in a way that made it possible to be retrieved, Astra could pull all the 
information and data from the databases needed to respond to the allegations. This 
was done despite the short timeframe (3 weeks) given by the German authorities to 
produce information on side effects registered in clinical trials.  
 
Market effects 
The effect these allegations from German authorities had on Astra was relatively 
insignificant, although the effects where never formally investigated. Sales of Losec 
diminished somewhat for a short period of time especially in Germany without having 
a big effect on its long-term growth.  
 
Losec was accountable for approximately 80% of Astra’s sales and was therefore a 
important product for the company. If Losec had been withdrawn from the market it 
could have had severe effects for Astra in a way that today’s status might not have 
been reached.  
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4.3.1 Key findings 
The Losec case can be seen as best case scenario because of how it was handled. The 
success can mainly be attributed to the proactive thinking of handling information 
from clinical studies. 
 
• Losec had been on the market for five years when it was implicated to causing 
visual disturbances and blindness. 
• An extensive organization within Astra was established that consisted of 
various teams of experts from within the organization.  
• An effective and uncomplicated hierarchical organizational structure 
contributed to solving the issue effectively. 
• The most important data and information needed to defend Losec were not 
available in the Losec medical database, since it was build to fulfill 
government regulations and not for scientific purpose. 
• The safety database was build for scientific use of data and information from 
CR studies and therefore proved an invaluable resource in defending Losec. 
• The market effects were minor to Astra although not fully examined at the 
time. 
 
What if questions 
What if the proactive thinking of collecting and managing information had not existed 
at the time? 
 
4.4 Case 2: Plendil (felodipine) 
 
Key facts: 
The drug Plendil (Felodipine) is a calcium channel blocker that works by decreasing 
the force of contraction of the heart muscle, decreasing the pressure of blood flow and 
improving the circulation of blood through the heart muscle. Plendil is mostly used to 
treat hypertension and angina. The product was first marketed in 1988. The sales of 
the product have been constant and somewhat increased in the period of 1997 - 2002 
from about $370 million to over $470 million respectively (AZ3). Today, Plendil is a 
part of AstraZeneca family of mature brands, generating considerable revenues for 
the organization although the patent for the drug began to run out in 1999-01 for the 
most part. 
 
 
 
Background 
In the beginning of 1995 there was panic over the use of calcium channel blockers to 
treat hypertensions and angina. The issue started with a presentation of a study at the 
35th annual conference on cardiovascular disease, epidemiology and prevention in 
March 1995 and was funded by the National Heart, Lung and blood Institute in USA. 
Following the conference and for several months a series of articles where published 
in science papers and media with many alarming stories to tell. Some of the headlines 
stated “Drug for Blood pressure linked to heart attacks: Researchers fear 6 million are 
imperiled” (The Washington Post, 1995). The study presented that rates of heart 
attack were higher among hypertensive patients taking a calcium channel blocker, risk 
Gunnar Gunnarsson & Jökull M. Steinarsson  Approaching Information Valuation 
 35 
 
as high as 70%, than among patients taking a first generation medicine such as beta-
blocker (Lenfant, 1995). Later there where even debates about other side effects like 
cancer, gastrointestinal bleeding and more that where supported by unsubstantiated 
research studies but provided enough information to fuel the debate.  
 
There where heated debates for about a year within the medical profession as well as 
among the general public on the suggested health risks of calcium channel blockers.  
Physicians took sides either supporting the arguments or criticizing them on the basis 
of their professional opinion or in some case their allegiance. There where several 
pharmaceutical companies that joined the debate in full force either prosecuting or 
defending the drug, based on their own particular business interest. The 
pharmaceutical companies that felt most threatened by the events where Bayer with 
Adalat (nifedipine), Pfizer with Norvasc (amlodipine) and AstraZeneca with Plendil 
(felodipine) (Mackay & Sever, 1996). 
 
The media used the opportunity they got to publish a potential sensational story and in 
the process criticize the medical profession and the pharmaceutical industry for 
providing “dangerous” drugs to the public. Even some of the pharmaceutical 
industries defensive tactics rose suspicions within the medical profession. The results 
where somewhat wide spread and in some cases resulted in risk full alterations in 
patient therapies, when either doctors or patients themselves changed their 
subscriptions with dire consequences for some (Mackay & Sever, 1996). 
 
The adverse side effects that where presented in the debate seemed to be only 
connected to first generation short acting calcium channel blockers (nifedipine). The 
strongest arguments from the pharmaceutical companies defending their products 
stated that it was not valid to conclude that these adverse side effects could be 
connected to the newer agents as nifedipine GITS, amlodipine and felodipine which 
provide positive effects due to their slower and longer duration of action and no heart 
rate effects (Mackay & Sever, 1996).  
 
The FDA held a hearing in January 1996 where all available information was 
reviewed which resulted in that no definite conclusion could be drawn from the 
information presented by either side and the use of calcium channel blockers could 
continue (Mackay & Sever, 1996).  
 
Internal view on the situation 
It became clear to people at Astra-Hässle rather early when the issue came up that it 
needed to put together resources to pull out security data on the product for analysis 
and potential presentation. In the beginning this was solely done as a preventive 
measure in order to be ready to respond to government request for information as well 
as preparing a document for publication to meet the general criticism if and when it 
came up.  
 
In this case where a whole class of medicine was under attack and more 
pharmaceutical organizations where involved the pressure wasn’t only on 
AstraZeneca to produce information. Rather all involved tried to produce information 
and use their contact networks to defend the medicine class for their own interest.  
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At the time of Astra-Hässle the roles and processes where of a more informal nature 
and not as defined groups as in today’s work environment. Therefore existing people 
that worked on the issue needed to some degree to drop everything else and focus on 
this issue at hand.  
 
The role of the marketing department 
Resources that where put together within the marketing department at AstraZeneca in 
Mölndal, where not extensive. From the beginning the issue was handled through 
changed priorities of existing local staff and resources. Within the marketing 
department it became most important to make decisions on how to act in such a 
situation, how to defend oneself and most importantly to communicate the 
information and strategies to the international sales offices who worked directly with 
customers. From a marketing point of view the question was how much damage and 
growth opportunities could be lost for the whole medicine class and how much the 
damages could be offset by sharing information to all parties involved including 
keeping people motivated to work both internally and within different countries on the 
issue. For the international sales offices it was important to have the same information 
in order to answer questions from customers, publish in local media and have 
prepared arguments to use at local events etc. The international marketing department 
was responsible for writing and distributing the correct information to international 
media, magazines as well as international congresses etc. In order to have the 
information needed there was a significant cooperation with the Drug Safety 
department in Mölndal. 
 
The role of the Drug Safety department 
The Drug safety department can be said to have had two customers that demanded 
information in connection to the issue, authorities and the marketing department in 
Mölndal.  
 
Information from clinical studies where divided to a large extent in two i.e. central 
data and data from local studies conducted by different sales offices around the world. 
The central safety database included serious adverse events (SAE) from both central 
and local studies but was missing complete information concerning less serious side 
effects or so called adverse events (AE) from clinical studies. The AE information 
was not available for direct search and therefore required extensive effort for the Drug 
Safety department to pull together from various resources. 
 
This proved to be the basis for the problem that Drug safety was confronted with since 
the AE information was needed in order to confront the issue. In order to amass the 
AE information a significant administrative work took place on preparing 
questionnaire for requesting the correct information about clinical studies conducted 
i.e. study name, how many patients included, how many and what specific side effects 
where registered. This questionnaire was sent to local sales offices in about 20 
countries. The communication with the sales offices proved to be quite resource 
demanding when firstly the right person needed to be found as well as extensive 
communication throughout the time it took to gather and register the information. 
There where several responses to the questionnaire that rose questions on the accuracy 
of the responses and as a result needed to be corrected, this was a time consuming 
process. 
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A central database was built specially for the purpose of entering the information from 
the questionnaire. There where some quality concerns about the fact that information 
needed to be keyed in to the database manually from the questionnaire papers. The 
whole process on amassing and analyzing the information took about 4-5 months.  
 
Mars 1995: the
first internal
memo about that
this issue should
be looked at.
May 1995: first
attempt made to
amass the required
information failed.
September 1995: a
critical situation came
up when UK
authorities requested a
list on clinical studies.
January 1996: the
analysis of the collected
data from clinical studies
was presented to an
expert panel in London
resolution; the use of
calcium channel blockers
could continue.
SepAguJulJunMayAprMar JanDecOct Nov
199619951988
1988: Plendil
(felodipine) first
marketed
 
 
Figure 4: Timeline in the Plendil case 
 
The issue demanded resources from various departments within Astra-Hässle 
including the medicine team for putting together the questionnaire, experts from 
IS/IT, experts on side effects, marketing people to judge the potential consequences 
from a marketing perspective as well as personnel from about 20 countries. An 
estimation done in 1996 showed that the effort of merely collecting the information 
for presentation to authorities took about 11 man months, as well as another 11 man 
months in lost time not including the efforts within each country. 
 
Market effects 
The market for calcium channel blockers was in 1996 around 8 billion dollars 
worldwide. Despite the lack of conclusive evidence against the overall use of the 
drugs, the controversy had a significant impact on the prescribing sales. Sales where 
registered to have decreased by 4% in the last quarter of 1995 while the concurring 
type of medicine experienced an increase in sales of 9% (Mackay & Sever, 1996).  
 
4.4.1 Key findings 
The Plendil case was resolved successfully but required extensive efforts in order to 
retrieve the information from clinical studies to effectively confront the issue. This 
included that the case was drawn out in time and became costly to resolve.  
 
• The medical class, that Plendil belonged to, was implicated to heart attacks. 
These implications were based on somewhat unsubstantiated research studies. 
• The media criticized the medical profession and the pharmaceutical industry 
for providing dangerous drugs to the public.  
• Since the information and the information environment was less structured 
than in the Losec case the first attempt on collecting the information failed. 
• The cost for collecting the information was estimated to be 11 man months 
plus lost time not including the effort within the 20 countries involved.  
• Information from clinical studies were divided into central data and data from 
local studies conducted by different sales offices.  
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o Central safety database included SAE’s from both central and local 
studies but was missing complete data from AE.  
o The AE information was not available for direct search and therefore 
required extensive effort since it was crucial in order to confront the 
issue. 
o Significant administrative work took place to collect the AE 
information and a central database was built.   
• A significant cooperation between the marketing- and the drug safety 
department took place in order to present the right information to the public 
and authorities. 
• Market effects were significant resulting in stagnating sales for the 
pharmaceutical companies in this drug class for approximately ten months.  
 
What if questions 
What if the information for Plendil had been structured in the same way as in the 
Losec case? 
What if Astra had not succeeded in presenting any information surrounding this case? 
 
4.5 Case 3: Bayer’s Baycol (cerivastatin) 
 
Key Facts: 
Baycol (cerivastatin) was a cholesterol lowering medicine. Medicines in this group 
are usually called “Statin” due to the active substance. The product was first 
marketed in 1997-98. In the year 2000 global sales of Baycol exceeded $586 million 
with forecast sales in the region of $1 billion for 2001. The withdrawal of Baycol was 
a high profile case that attracted significant media and public attention.   
 
 
 
Background 
Bayer pharmaceuticals business group represent about 20% of Bayer AG, with 
approximately 25 thousand employees and about $5 billion in annual sales in 2002. 
[URL9]  
 
The cholesterol lowering medicine Baycol had been on the market for about four 
years when in the beginning of 2001 reports began to surface about patients deaths in 
the US as a result from using statins.  
 
Cerivastatin was the most potent statin on the market, effective in fractions of 
milligrams (mg). Concern arose as a result of deaths from a severe muscle weakness 
(rhabdomyolysis) in the United States, 40% of which were associated with 
prescriptions of the drug in combination with Lopid (gemfibrozil), which is also a 
cholesterol-lowering drug. In June 2001, Bayer modified the label on Baycol after 
reports of patients suffering rhabdomyolysis. Deaths linked to cerivastatin continued 
to be reported despite two warning letters to United States’ doctors advising them to 
start cerivastatin with the lowest available dose and not to prescribe cerivastatin with 
gemfibrozil. (Wright et al., 2002) 
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Bayer stated that the adverse events reported with Baycol were not specific to Baycol 
and had been observed in patients receiving a number of different statins. Bayer also 
stressed that, if Baycol was prescribed as directed these events should not occur 
[URL9]. Nevertheless, in the wake of the developments and the fact that all attempts 
to defend the drug as well as give warnings to doctors, pharmacist and authorities 
failed, Bayer pharmaceutical division voluntarily withdrew Baycol from the market, 
August 8, 2001. (SoRelle, 2001)  
 
A story in the August 9, 2001, New York Times said the removal was made because 
of 31 deaths that had been linked to the cholesterol lowering medicine and a further 
10 patients in Europe. The deaths were linked to a condition that causes muscle cells 
to break down, releasing their contents into the bloodstream and in severe cases can 
lead to kidney and other organ failure. Those patients at highest risk for developing 
rhabdomyolysis were taking a large dose of Baycol in combination with Lopid. 
(SoRelle, 2001) 
 
The statin risk in context 
Baycol was withdrawn from the world market because there were increased reports on 
muscle deceases (myopathy) and several instances of fatal rhabdomyolysis. Prior to 
the large dose of the drug no serious safety concerns had been observed. However, the 
risk of rhabdomyolysis greatly increased when Baycol was used at high doses or when 
administered in combination with Lopid. In a presentation by Professor Shepherd at 
the international symposium on atheroscleosis (ISA) congress in Kyoto 2003 was 
noted that the risk of rhabdomyolysis was much greater with cervastatin that with the 
other statins. Despite extensive testing, this had not been observed prior to the launch 
of the product. (Shepherd, 2003) 
 
Much of the safety data for medicine is accumulated from adverse event reports 
during early drug development and from randomized clinical trials. However, 
relatively small numbers of patients are used in these studies and rare adverse events 
may not be observed. Furthermore, patients with poor health or associated 
medications that may increase the risk of adverse events are often excluded from 
clinical trials. Therefore, it is not until post marketing surveillance, when a medicine 
is used in large numbers of patients, that many adverse effects are observed. Professor 
Shepherd also noted that out of 484 million statin prescriptions in the USA, only 73 
cases of rhabdomyolysis had occurred. (Shepherd, 2003) 
 
Market effects 
The global statin market is the largest drug class in the world with sales reaching 
$16.7 billion in 2000 [URL10]. These sales are fiercely fought over by many of the 
world’s biggest pharmaceutical companies. Therefore, although the withdrawal was 
devastating for Bayer it created opportunities for their competitors. Bristol Myers-
Squibb, Novartis, Pfizer and Merck enjoyed from 50-200% sales growth, to a large 
extent, as a results of the Baycol withdrawal. [URL11] 
 
Effects on Bayer 
The impact of the withdrawal on Bayer was significant. Not only did it lower the 
return on the R&D investment Bayer had made on Baycol’s development, it also 
threatened the company’s reputation and profitability as a whole. Sales of the drug 
accounted for about 25% of Bayers pharmaceuticals business group, so the 
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withdrawal left a significant hole. The drug had been forecasted to generate sales 
close to $1 billion in 2001 [URL11]. Bayer AG has been forced to cut more than 
4.000 jobs and close 15 sites within its operation in order to reduce costs since the 
withdrawal. The threat of legal action and lawsuits was estimated to cost the company 
between $200 million and $3 billion. [URL11] 
 
Bayer has paid $614 million (as of October 2003) to settle 1.683 cases out of court. 
The company will continue with their settlement policy trying to agree on a fair 
compensation for anyone who experienced serious side effects from Baycol on their 
own initiative and without acknowledging any legal liability. The drug is linked to 
more than 100 deaths since Bayer recalled Baycol in August 2001 and according to 
Bayer website the company now faces 11.300 cases because of the drug. [URL12] 
 
After the withdrawal of Baycol there was talk at Bayer about abandoning the 
pharmaceutical operation altogether but it seems unlikely that that will be the case. 
 
March 2001:
Potential problems
with Baycol emerge
- rumors of muscle
weaknesses.
June 2001: Bayer
amends label on
Baycol after reports
of patients suffering
muscle weaknesses.
June - August: Bayer denies
AEs reported with Baycol,
not specific to Baycol,
claimes they were observed
in patients on other statins.
August 8, 2001: Bayer
withdraws Baycol from
all markets, except Japan,
following reports of 41
patients deaths from
rhadomyolysis in US &
Europe.
JunMayAprMar AguJul
200120011997
1997: Baycol
(cerivastatin) first
marketed.
Oct. 17, 2003: Bayer has
settled 1683 cases, of
approx. 11.300, and paid
$614 million in damages.
Average settlement
between $3-400 thousand.
2003
 
Figure 5: Timeline in the Baycol case 
 
Regulatory effects 
The FDA is expected to review information concerning side effects more rigorously 
in the light of the concerns surrounding the Baycol case and be more cautious of 
approving new statin therapies [URL11]. Even the European Medicines Evaluation 
Agency (EMEA) has promised to get tough with pharmaceutical companies if they 
fail to follow its rules for reporting product side-effects. It may resort to naming and 
shaming those that do not comply and could even prosecute offenders (Pharmacutical 
Executive, 2002). 
 
As several high-profile medicine withdrawals have shown, no matter how carefully 
companies carry out and analyze Phase III trials (clinical studies on humans), those 
studies are not extensive enough to pick up all potential serious adverse reactions that 
more widespread use may reveal.  
 
There have been heated discussions on if it is really necessary to withdraw a drug 
from the market because of side effects. Although some patients obviously suffer 
because of the drug, many more experience benefits. But, the potential legal 
implications of leaving a “killer drug” on the market appear to be weighing more 
heavily on the corporate minds of pharmaceutical companies. (The Pharmaceutical 
Journal, 2001) 
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After Bayer’s decision to take Baycol off the market, the issue of drug withdrawals 
has become strongly debated within the pharmaceutical industry. The effects of a 
product withdrawal go beyond a fall in the company’s revenues, affecting the 
pharmaceutical industry as a whole. [URL11]  
 
When the incident with Baycol occurred, AstraZeneca was in the late stages of 
developing a new statin, Crestor. The approval for Crestor was in fact affected as a 
result of the Baycol case, being delayed for several months wile the statin affects 
where researched in more detail. Today, Crestor has been launched in 22 countries 
and approved in 40 countries around the world. 
 
4.5.1 Key findings 
The Bayer case can be considered as a worst-case scenario for several reasons. 
Although some of the key findings can only be speculative due to the lack of having 
first hand information from within Bayer for obvious reasons. 
 
• Baycol had been on the marked for 4 years and was one of many drugs within 
the so-called statin class. 
• Baycol generated serious side effects because of two reasons. 
o Wrong dosage administration, although Bayer in later stages came out 
with recommendations for optimal dosage with little compliance from 
the market. 
o Prescription combination of another frequently administrated dug. 
• Bayer tried to argue the case for Baycol and tone down the significance of the 
adverse events by stating that they where not specific to Baycol. 
• Risk of serious adverse events was noted to be greater with cerevastatin 
(Baycol) than any other statin on the marked by leading marked opinion 
leaders. 
• Baycol was tested prior to its launch without the severe adverse events being 
observed. 
o Relatively small number of patient in clinical trials. 
o Safety data is collected during early development from randomized 
clinical trials. 
o Patients with poor health and associated medication often excluded. 
• Statistically there was a low likelihood of this particular SAE occurring; only 
73 cases out of 484 million prescriptions were registered in USA. 
• Baycol voluntarily withdrawn from the market in august 2001, 4 years after its 
launch, i.e. 6 months after the issue came up. 
• The case had no visible negative effects in the statin market as a whole 
although other statin pharmaceutical companies enjoyed a significant increase 
in sales after Baycols withdrawal. 
• Effects to Bayer have been extensive, 
o Bayer lost approximately 25% of its pharmaceutical business as a 
result of Baycol withdrawal. 
o Sales where projected to grow approximately 70% between 2000 and 
2001, from $586 million to $1 billion respectively. 
o Downsizing within the Bayer group; 4000 laid off and 15 operations 
sites closed. 
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o Legal actions; compensations as of October 2003 $614 million in 1.683 
cases settled out of court, face more than 11.000 cases, damages could 
reach up to $3 billion.  
o Discussion on withdrawing from the pharmaceutical business 
altogether. 
 
What if questions 
What if they had monitored the market more closely for reports on SAEs? 
What if they’d had an infrastructure for analyzing market data? 
What if they had acted quicker to the reports/rumors on AEs? 
What if they knew about the problem but did not act on the information? 
 
4.6 Case 4: Exanta (ximelagatran) and consolidated clinical data 
storage 
 
Key facts:  
Exanta (ximelagatran) is a new class of medicine that is called oral direct thrombin 
inhibitor and works to prevent blood clotting (coagulation). The drug is in the last 
stages of development, currently being submitted for an approval worldwide (2002-
04) and is expected to become a mega brand for AstraZeneca.  
Consolidated clinical data storage (CCDS) is a proposal for a future information 
environment for capturing, storing, retrieving and sharing clinical study data.  
 
 
 
Background 
The proposed solution of consolidated clinical data storage (CCDS) provides a secure 
place for electronically stored clinical study data, product information and indications 
for quick and easy availability and utilizations. The solution is planned to give 
authorized users ability to access the information using the means they are most 
comfortable with.  
 
The use of CCDS for Exanta information and data was as a first step planned to focus 
on being a risk management platform able to handle issues that come up i.e. Adverse 
Events (AE) and Severe Adverse Events (SAE). This initial step has been advanced 
and today the use of CCDS for Exanta can be seen more as a risk/benefit platform 
helping to identify and react to both positive and negative effects of a drug. This will 
enable the teams to be more proactive when it comes to defending the drug, 
identifying unknown potentials by having immediate access to basic studies. 
Normally, in today’s information environment this is achieved reactively, when 
absolutely needed for some reason or another. Such solution more often than not 
require a group of people to work and being time consuming therefore only effective 
when absolutely necessary. 
 
Present clinical study information environment  
All AstraZeneca drug safety units and marketing companies have the responsibility to 
report all Adverse Events (AE) and Severe Adverse Events (SAE) in a report form 
into a central database called Clintrace Data Entry Site (CDES) in Mölndal. CDES is 
a document storage and information resource on all Adverse Events. Usually AEs are 
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reported at the end of each study while SAEs follow a stringent reporting structure 
demanded by authorities with serious consequences to the pharmaceutical company 
that delays its reporting. This structure has somewhat limiting usability i.e. not 
providing immediate access to information and data or any function for cross-
referencing studies. 
 
All knowledge that is captured from Clinical research information is stored within 
Global Electronic Library (GEL) and in the Product Knowledge Transfer (PKT) 
system. Regulatory reports are stored in GEL and PKT is a knowledge base that 
functions well for crossing over from R&D thinking to a marketing mindset, 
containing published scientific articles and information used mainly for marketing 
purposes. The main distinction from the proposed CCDS is that GEL and PKT 
contain extensive quantity of reports; articles and abstracts based on clinical science 
data or facts from documents that have been structured and packaged specially and 
sent to authorities while with CCDS the focus is on clinical data and its structure to 
enable internal exploitation. Today the clinical data is more or less not reused and 
essentially archived.  
 
Extensive work has been put into building the current structure for accommodating 
flexibility for information and data utilization supporting the requirement to submit 
information to regulatory authorities. Primarily information coming from clinical 
studies are organized in a structure providing a document interchange format between 
industry and regulatory agencies. Meaning that, clinical documents are stored in a 
folder structure comprising a comprehensive table of contents [URL13] enabling data 
reviewers to navigate electronic submissions and clinical data within datasets per 
study and per domain (e.g. demographics, vital signs, adverse events) “suitable for 
reproducing and confirming analyses” [URL14,15]. This means that the data and 
documents are organized according to demanded by international authorities like the 
American food and drug administration (FDA), which can be argued as not being the 
optimal way for reuse within the organization.    
 
Exanta benefits from CCDS 
Exanta will be the first drug to benefit from the new information environment and the 
experience will be used for a continued development and expansion of the CCDS 
project. One of the advantages for the people working on the new drug Exanta will be 
that they will go from the former way of having data from each clinical study in 
separate datasets to being able to have access to integrated and consolidated data from 
across studies. This will enable analysis of the whole population of data from patients 
that have had the Exanta drug in clinical studies, approximately 30 thousand patients 
from 80 studies to date.  
 
The mean cost for a clinical study patient has been calculated as being about $8000. 
This figure is important to highlight since this cost is fixed and unrelated to how the 
information is used or reused later on. Therefore it can be seen as significant 
improvement to the clinical study investment if data can be used more extensively.  
 
Analysis and visualization of integrated and consolidated clinical study data will be 
available for authorized users from the scope and detail that is of interest to each and 
within their defined level of access, often being to support the continued development 
of the drug effects in detail.   
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CCDS information environment 
The proposed platform will be designed as a classic data warehouse (DW) application 
utilizing an established and tested techniques for extracting, transforming and loading 
(ETL) data from different sources to a single pool of data storage.  
 
It seems very trivial not being able to pool data from all submitted studies today, 
probably due to the fact that each project has been able to establish and have its own 
focus and different traditions developed. The fact remains that there hasn’t been a 
single registration environment available due in large part to the uniqueness of clinical 
studies and the geographical structure of the companies in different sites world wide. 
With DW technology and ETL tools this can be remedied, nonetheless requiring 
extensive modeling and standardization.  
 
The data will be linked together in order to be easily searchable as well as being 
profiled in a proper scientific and business context. The data will be linked to 
metadata details about different types of clinical study items (variables) to be accessed 
in a sort of clinical reference library.  
 
The platform is thought to include a information model that is capable of integrating 
data and information in a extensible and robust way. The model will be capable of 
loading, organizing, combining and integrating clinical data both the study results as 
well as information about and surrounding the study itself. The model that will be 
constructed will be the key to how information and data are extracted from various 
operational sources and organized for usable presentation of information. The CCDS 
will be the key to use and reuse of data from clinical studies.  
 
Users of CCDS 
Initially the users of CCDS will primarily be a combination of representatives from 
each therapy area (TA), in this case concerning Exanta, having access to all data for 
statistical and medicine analysis.  
 
Researchers from the group Key brand team involved in further development of the 
drug will have access to data within CCDS. The Key brand team will also have access 
to information in context to scientific articles, abstracts or studies.  
 
Other researchers will use the system in order to address questions and defend issues 
that come up through and beyond the lifecycle of the drug i.e. act as the defending 
mechanism within the company. Operational users such as those working with 
biostatistics etc. will benefit from receiving data in earlier stages of development. 
 
A DW such as CCDS is often referred to as a “drifting” system where the use and 
users initially thought for the system will evolve over time (Ciborra, 2002). Therefore, 
users that can be seen to benefit from using the system today might be different in the 
future. Some potential areas of future use can be seen to be within project related 
areas like project development, - management, - progress monitoring and - planning. 
 
Initiators and the cost of the new information environment 
The key initiators of the project come from the Medical Informatics department in 
Mölndal, which is along with the Information Systems department (IS) responsible for 
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the architecture and development of the CCDS. Operational departments, such as 
Drug Safety, Experimental Medicine and Clinical Information Management, are 
directly involved in the development of the project and give their input to the 
platforms functions and functionalities.  
 
Initial cost for building and implementing the platform is estimated to be about 9 
man- years ($100.000). The platform will eventually replace other information 
initiatives for extracting and transforming of clinical data, which will result in a 
operational cost reduction in the long run.  
 
Authorities and data interchange 
The increasing demands from authorities has resulted in a more stringent regulations 
on the pharmaceutical industry which has in turn increased their work and shortened 
the response time for reporting on medicine side effects. In the environment of 
tomorrow where authorities have developed solutions that allow them to do their own 
cross studies on medicines and projects internal solutions need to be competitive. 
 
International authorities, particularly US, have required pharmaceuticals to follow 
standards for electronic data interchange and submission. The US Clinical data 
interchange standard committee (CDISC) has applied a standard for submission of 
clinical data, first with the requirements included in the so called item 11 standard 
which is being further developed based on an improved conceptual model. Being a 
specialization for the clinical domain from the generic HL7 Reference Information 
Model (RIM) [URL16], which is an information model for clinical -, administrative -, 
financial data, documents and structures (e.g. structure of electronic health record).  
 
The FDA is also in the midst of developing a conceptual model for their data 
warehouse (called JANUS) that will be used for collecting information from clinical 
studies from different organizations and with capability for doing cross-references 
between drugs within diverse therapy areas. The JANUS project is being looked at as 
a potential standard for the CCDS core information model. 
 
Challenges 
The biggest challenges of developing the platform are not seen as being technical, 
although it will be challenging, but rather the issues of ownership and governance of 
data and metadata i.e. not the development but the administration in the long run. The 
ownership of data and metadata needs to get a greater focus within the project and 
perhaps within the organization in a wider sense.  
 
4.6.1 Key findings 
The project of building an information environment for Exanta is a future vision for 
optimal usage of clinical study information. 
 
• Currently all data from clinical studies are stored in flat files and folders and 
not easily analyzed and not cross-referenced. 
• Today the Clintrace database houses all AE data from clinical studies and a 
knowledge base of articles and abstracts is maintained in the product 
knowledge transfer database. 
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• New information environment is for handling risks and benefits of medicine 
clinical study information. 
• The aim is proactive thinking for handling issues. 
• Exanta will be the first drug to benefit from the new information environment 
and cross-referenced clinical studies. 
• Clinical study data is used for submission to authorities and as references to 
scientific articles and thereafter archived. Clinical studies have a mean cost of 
approximately $8000 per patient and Exanta clinical studies have included 
30.000 patients to date. 
• Technically the solution is planned to be based on standard data warehouse 
and extract, transform and load (ETL) technologies. 
• CCDS is a part of the new information environment that is planned to be the 
key to clinical study information and data reusability. 
• The estimated project cost is nine man-years ($100 thousand) and the 
environment is expected to replace some current systems that will result in 
operational savings. 
• In the environment of tomorrow where authorities have developed solutions 
that allow them to do their own cross studies on medicines and projects 
internal solutions need to be competitive. 
 
What if questions 
What if a serious issue came up today regarding e.g. Exanta, how would it be handled 
in the today’s information environment?  
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5 Analysis 
In this chapter the material from the case studies is analyzed and put in context with 
the literature review presented in chapter 2. The cases are analyzed from an 
information value and risk perspective as well as going through approaching 
information valuation based on several reasons relevant to the cases.  
 
5.1 Case analysis from a risk perspective 
When studying the different risk aspects within the cases, in relation to different 
medicine statuses on the market, the risks can be divided into four categories; first in 
class, second in class, the whole medicine class and one particular medicine in a class 
(interview with Dimenäs, 2003). The following analysis is done in order to put in 
context the general risk of each medicine presented in the cases. 
 
First in class means, that it is the first medicine of a new class of compounds that is 
launched. Therefore, when a pharmaceutical company launches a first medicine in a 
class it is not without a risk. Often competitors with the help of media “attack” the 
medicine with negative implications and spread fear, uncertainty and doubt into the 
minds of the public and professionals, e.g. with the aim of protecting current market 
share. For the company that is marketing a first in class medicine it is a challenge to 
prove the concept combined with the competitors having established medicines in the 
market trying to question the approach. In order to succeed the medicine has to be 
considerably better than its competitors and needs to go through the process of 
establishing a name in the market as well as not being able to benefit from previous 
experience from e.g. market information, extensive scientific articles etc. From a 
clinical research perspective the risk for a first in class medicine not gaining 
significant market penetration can be said to be medium to high. Losec and Exanta are 
considered to belong to the risk aspects of a first in class medicine since they are 
examples of the first medicines in their class for treating acid related disorders and 
preventing blood clotting administered orally, respectively. 
 
Second in class refers to launch of a compound where there are already at least one 
available, which therefore can be considered to pertain even less risk whereas its 
predecessor already is known and established in the class as well as making it possible 
to build on the in-house experience from its already known and documented 
forerunner. An example of a second in class medicine from AstraZeneca is Nexium 
(although not a subject of the case study in this report), which was a follow-up 
medicine to Losec. Risk of medicine withdrawal can be considered low.  
 
The whole medicine class risk means that a whole class of medicines is subjected to 
accusations of not being safe e.g. causing harmful side effects or not being effective. 
Similar risk can be identified in the Plendil case, were the whole class was blamed for 
causing serious side effects and not being applicable medicine. The risk that a whole 
medicine class is “attacked” can be considered low, but even less so that one medicine 
in such “attack” is singled out and possibly withdrawn.  
 
The Baycol case is an example of one medicine in a large medicine class that is 
accused of causing serious side effects and is an example of the fourth risk aspect, one 
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medicine in a class. Baycol was a single medicine accused of causing severe side 
effects, which led to its withdrawal from the market. The risk of this happening can be 
considered low in general. While, there was also the medicine combination effect, 
relevant in the Baycol case which can be seen to be a shared risk more or less within 
all the medicine classes. 
 
Having gone through identifying and categorizing the risk aspects of the medicines it 
can be said that the risks mentioned can be reduced significantly by having proactive 
thinking when it comes to information management, case in point Losec and the 
future case associated with Exanta’s information environment. Although for the 
purpose of this thesis the information management strategy and valuation are 
highlighted it is by no means meant as a suggestion for the replacement of a more 
traditional operational risk management, which is extensive within AstraZeneca e.g. 
when it comes to reducing the risk of new medicine development and within clinical 
trials. 
 
Even though, it is mentioned that the risk of not having data and information available 
to spot trends of negative effects, like is implied in the Baycol and Plendil cases, it 
must be mentioned that the clinical study information and data would not have 
contained any indications of those side effects since the studies where in all 
probability not designed to focus on the particular issues that came up. Although, 
being able to analyze marketing information and data would probably have helped 
and the risk increases somewhat when it is not centrally known what studies are 
ongoing, especially if no information from these studies are readily available for 
analysis and cross-reference.  
 
5.2 Approaching information valuation  
Based on the cases studied and the information value theories, a valuation of clinical 
research (CR) information can be considered to be more applicable if based on 
qualitative value associations. The reason being high uncertainty of future events, 
therefore inability to establish a practical quantitative value, as well as differences in 
risk between medicine classes that can lead to misunderstanding of the valuation. 
 
The approach in this chapter is based to some extent on Poore’s (see chapter 2.1.8) 
approach to information valuation for security risk management, although somewhat 
modified for the purpose of this analysis. His method is used to establish a framework 
for the analysis of the cases in the empirical study, establishing connections between 
reasons for valuing information and risk factors that can have effect on information. 
The analysis establishes a connection between reasons for valuing information and the 
various risks factors in order to highlight and prepare possible defense techniques for 
risk evasion.  
 
5.2.1 Information risk factors 
According to Poore (2000) there are three security risk elements that affect 
information valuation for risk management which are, confidentiality, integrity and 
availability. He further explains that each element may have a value independent of 
(or in some cases interdependent with) the others and when searching for the value of 
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information, focus should be on the categories most directly related to the reason for 
the valuation.  
 
For the purpose of this thesis, Poore’s information security elements have been 
adapted and identified as information risk factors that in a similar sense affect the 
information valuation for risk management. Same as before, confidentiality, integrity 
and availability are seen as important aspects of information valuation, but even 
reusability. The additional risk factor is seen as significant in the sense that it is a 
determining factor for information value as established in the literature review.  
 
The reason for making the multidimensional valuation is to bring to light risk factors 
that can affect information value. Table 6 shows the mapping of information value of 
CR information with the four risk factors that have been identified as important in the 
information valuation process. 
 
Risk factors 
Inf. value 
Reusability Confidentialit
y 
Availability Integrity 
Exclusive possession  x   
Utility x  x  
Original cost or cost of 
re-creation 
  x  
Potential liability x x x x 
Operational impact x  x x 
 
Table 6: Multidimensional information valuation for CR information 
 
From a risk management perspective a close consideration ought to be on the risk 
factors since the more attention and commitment is made on reducing these risks i.e. 
increasing their status and focus through various commitments in IT/IS, the more 
valuable CR information can be considered to get. 
 
5.2.2 Reasons for information valuations accounting for information risk 
factors based on the case analysis 
 
Exclusive possession 
Since pharmaceutical companies are required by law to submit all information from 
clinical trials exclusive possession can be redundant to uphold for information 
valuation purposes. It is inevitable that CR information will become known to 
authorities or competitors at some stage, which can be seen in the Baycol case where 
authorities seemed to be quicker than Bayer to discover and analyze information 
relating to the SAE’s. Nevertheless, valuing CR information can be based on its 
exclusive possession at some stage in its lifecycle e.g. when it can be deemed harmful 
to the company if information is prematurely released (e.g. incomplete information 
that can be misinterpreted) and seen by competitors, authorities etc, therefore 
exclusive possession is preferred. Furthermore it can be vital to have exclusive 
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possession of CR information that includes or can lead to important discovery and 
new products.  
 
Information risk factors 
If CR information is considered to remain in exclusive possession a particular concern 
should be made on protecting its confidentiality while other risk factors can be seen as 
less important. 
 
Utility 
In the Losec and Plendil cases a safety database containing clinical data and 
information was available. The database was built for scientific reasons to contain 
safety data and information from all medicines of concern to Astra Mölndal, with the 
purpose of making cross-references and discover trends and side effects early on. 
Information is generally accepted as increasing in value with use as well as when it is 
combined with other related information. Information is also thought to be as least as 
valuable as the use it is put to. Therefore, this proved to be particularly proactive 
thinking at that time, giving the tone for the information value, even when compared 
to the market as a whole.  
 
Losec was an important product to Astra and it was deemed essential to organize all 
its data and information in a way that it could be easily accessed and analyzed. From 
an information value perspective this is in line with Skyrme (1994) thoughts on 
adding value to information, through the value adding principles like accessibility, 
usability, quality and reusability. Nonetheless, the Plendil case demonstrated that 
information sharing and availability was not entirely perfect, having negative effects 
on its value. The issue handling in the Plendil case forced the organization to work 
reactively, which proved to be time consuming, demanding significant and costly 
resources, all stemming from unavailable information and data.  
 
Clinical research information cannot be said to possess utility value in a traditional 
sense (transactional monetary value) but nevertheless possessing value based on its 
use. According to Glazer (1993), most organizational resources show decreasing 
returns to use but information increases in value the more it is used. When 
determining the utility value of CR information it is important to consider, as 
mentioned before, that the information is at least as valuable as the use it’s put to. But, 
since CR information is not used for revenue generation no revenue stream can be 
directly linked to it. Nevertheless, CR information can be seen to have a utility value 
for research and discovery, whereas it can be used to shorten time to market and 
identify previously unknown potentials, which can lead to new product discovery. In 
that respect it would be possible to reach a qualitative value based on its future 
potential, although it would be highly subjective. 
 
In the Bayer case, not being able to pull information could mean that the information 
environment did not provide them with enough information availability and 
reusability, which lessened its value. From a risk management perspective the CR 
information needs to be in such a condition (see chapter 2.2) that it is reusable for 
defense purposes. That being said, the utility value from a risk management (defense) 
perspective can be essential in the lifecycle of a medicine when an issue occurs. The 
CR information should be accurate and available in order to be useful, avoiding costly 
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regeneration of CR information. Therefore a significant value portion of the 
information can be justifiably used for building a risk platform.  
 
Information risk factors 
The utility value of CR information is its use within the development of a medicine, 
scientific knowledge, shortening time to market, new product discovery and reporting 
to authorities. In that sense the risk factors of reusability and availability are 
considered to be most directly related to the valuation. Confidentiality and integrity 
seems less important (although important to some extent) because of the reporting 
requirement to authorities as well as demands for publishing the results of CR in the 
scientific community.  
 
Original cost or cost of re-creation 
The safety database included safety data from Plendil as well as several other 
medicines as previously mentioned and in that respect consistent with the Losec case. 
The main difference between the cases is that a complete information from Plendil 
clinical studies where not readily available centrally. This turned out to be one of the 
main reasons for the difficulty when amassing the information needed to resolve the 
issue. The missing information in question concerned adverse events that were stored 
locally at local marketing companies. The information was important and needed to 
be available and analyzed in relation to the issue, which meant that significant 
administrative work needed to take place as well as building of a simple central 
database that could store the collected information. In a way it can be said that the 
information needed to be partly recreated centrally. Therefore the conservative 
method of assigning value to information based on how much it costs to acquire the 
information (Moody and Walsh, Poore et al.) is possible. If the information could be 
recreated for approximately the same cost the value is useful from a risk management 
perspective, but if the process cannot be repeated or it is too expensive the original 
cost of creation is not a good indicator for its value. The quantitative value of CR 
information could in that sense be said to be the cost of its acquisition, adjusted with 
relevant laws of information presented in chapter 2.1.2.  
 
Information risk factors 
If CR information value is to be based on the original cost or cost of re-creation the 
risk factor availability is considered to be the most relevant risk factor. The focus 
should be on keeping the information available so that the risk for re-creation is 
minimized. 
 
Potential liability 
The cholesterol lowering medicine Baycol was linked to many deaths and as a result it 
was withdrawn from the market. Although it is difficult to make a conclusive analysis 
from the case due to how little information there is concerning the information 
management at Bayer, it is possible to draw some conclusions. How Bayer handled 
the information they should have possessed, coming from clinical research and 
market, can be seen as being ineffective and inefficient when it comes to information 
management and utilization. By not acting on the information they had, due to some 
reason or another, the organization failed to respond to the situation that came up in a 
timely manner. Although, since authorities were able to pull and research information 
and data concerning Baycol, one can draw a conclusion that Bayer should have been 
able to do the same. By not acting on the issue earlier, as was apparent, suggests that 
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Bayer had the information but did not use it. Therefore from an information value 
perspective, information that cannot be used by those who possess it may actually 
have a negative value, that is, it may represent an extra expense or a liability (Poore, 
2000).  
 
Losec was a first in class medicine competing in a large market where competitors 
and media focused on side effects and not the positive effects of the medicine. Since 
Losec was Astra’s biggest medicine it became apparent to individuals within the drug 
safety group that a safety database would be needed in order to respond to issues that 
could occur. 
 
When information represents a relationship of trust (e.g. because of its personal or 
private nature, trade secrecy) then the person that possesses the information may 
assume liability for its protection (Poore, 2000). Clinical research information is both 
personal and private and therefore can the person/patient assume liability if the 
company (AstraZeneca) fails to protect it. From a risk management perspective the 
CR information in this context constitutes confidentiality and integrity. Poore suggests 
that, “If the information is itself a warning of a condition opposite to law, safety, or 
the interests of third parties, the company may cause it to have value by failing to act 
on it”. In that respect it would mean that if the organization fails to notify patient/s of 
any irregularities, based on CR information, concerning his/her treatment the patient 
can assume liability. A quantitative valuation of CR and marketing information 
concerning Baycol, where third party was involved and resulted in thousands of 
lawsuits against the company with an estimated cost of up to $3 billion is possible, 
although highly subjective and therefore not likely. Obviously these figures are too 
high and not practical to value CR information that high but this can be used to give 
some idea of the impact based on previous knowledge. 
 
Information risk factors 
For an organization to be able to protect itself, in a timely manner and minimize the 
threat of potential liability it is important that CR information is available for analysis 
in order to protecting the integrity of the organization. If a potential liability is 
eminent it can be dealt with in a more efficient way if CR information is readily 
available in a reusable form to be accessed and presented in a timely manner, 
comparable to the Losec case. 
 
Operational impact 
It can be pertinent for the organizations to assign a value to CR information based on 
the impact that the absence of the information would have on the organization. 
Similarly, base the valuation on the impact that incorrect or untimely information 
would have (Poore, 2000). Therefore, CR information can be valued based on the 
severity of an impact that an issue could have on the company e.g. if CR information 
is inaccurate or none existent. Having unavailable and inaccurate information can 
result in harmful affects, but by quantifying the impact, based on previous experience, 
it is possible to use it for information valuation for risk management purposes.  
 
An example of operational impact can be seen in the Baycol case where the medicine 
needed to be withdrawn costing Bayer 25% of its operation and future earnings, a 
figure that is estimated to be several billion dollars. If a valuation based on operational 
impact is applied to the Losec case given that the information had not been available 
Gunnar Gunnarsson & Jökull M. Steinarsson  Approaching Information Valuation 
 53 
 
or not accurate, a qualitative valuation would also be an extreme amount based on 
sales loss estimation due to medicine modifications, delays and reduced market share. 
Comparable to basing information value on potential liability the figures are 
extremely high and it is not practical to value CR information in that sense, but can be 
used to give an idea of the impact based on previous knowledge.  
 
Information risk factors 
From an information value perspective in order to minimize the risk of operational 
impact it is important that CR information is made available and reusable through 
various information systems for defense purposes as well as to preserve organizational 
integrity. Confidentiality can be seen to be less important (although important to some 
extent) because of the reporting requirement to authorities as well as demands for 
publishing the results of CR in the scientific community. 
 
5.2.3 Clinical research information value indicators 
Based on the case analysis in the previous section the following summary can be 
made of the information value indicators that were identified. The indicators can be 
further developed into representing active value for CR information.  
 
Quantitative value: can be both positive and negative where the summation of the two 
gives the total value 
• How much it cost to acquire or recreate the information (adjusted with e.g. 
use, shelf life, accuracy) 
• Operational impact of non available and reusable information (e.g. Bayer case) 
• Liability (e.g. Bayer case) 
 
Qualitative value: information value can be ranked from least to most  
• Defense value (e.g. issue management) 
• Medicine development, scientific knowledge, shorten time to market, 
reporting to authorities  
• Can lead to important discovery of previously unknown potentials and new 
product development (R&D value) 
• Protecting third party privacy 
• Early indication of harmful effects 
• Medicine integrity - at some stage CR information can be deemed harmful if 
released prematurely 
  
5.3 Recommendations  
The focus within this thesis has been on clinical research information therefore the 
recommendations are subjective in that respect. When approaching the valuation of 
information it is important to keep in mind that there are significant differences 
between the available valuation methods/theories and the purpose of the valuation as 
well as the nature of the information itself. As an example, a valuation for accounting 
purposes can differ significantly from a valuation for defense purposes, as is the 
subject of this thesis. The accounting approach establishes usually a value for 
presentation within a financial statement e.g. accounting for non-hardware 
information technology resources, market value of information or registers a value of 
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a R&D undertaking. The approach of this thesis is to use the experience gained from 
going through the valuation process to approach information value in order to support 
decisions on information systems and information management efforts for risk 
evasion purposes.  
 
The following approach summarizes how the organization could go through the 
process of valuing its information assets for defense purposes.  
 
 
 
Risk analysis
Reason & purpose of the
information valuation
Quantitative and/or
qualitative valuation
Information risk
factors
Risk Management
- What focus
- Information value
Decision on
investment in IT/IS
What focus
In
fo
. v
al
ue
 
 
Figure 5: Method for approaching information value 
 
 
The process of valuing information is best approached by a group of individuals with 
a compiled knowledge of the information to be valued, prior experience working with 
risk and market familiarity. The group establishes a reason and a purpose for valuing 
the information whereas information, by its nature, can have multiple values 
correlated to the reason for the valuation. In this thesis the focus has been on the 
reasons as presented by Poore; exclusive possession, utility, original cost or cost of re-
creation, potential liability and operational impact. It is possible that more than one 
reason may apply or other reasons can be identified as being more appropriate. 
Nevertheless, some or all of the mentioned reasons are most often suitable to base on 
a valuation for risk management reasons.  
 
Given the nature of CR information the authors of this thesis have observed that 
arriving at a valuation, whether qualitative or quantitative, is highly subjective and 
based on individual or collective assessment. Nevertheless, the method can be used to 
give an indication of an information value. Therefore, having established the reason(s) 
for the valuation a process to identify possible quantitative or qualitative (or both) 
aspects of the information is done. As an example; assuming that a operational impact 
and potential liability are the basis of the valuation the next step would be to identify 
different situations that could occur if information is inaccurate or missing, 
considering the probability of the occurrence. The outcome of the process gives an 
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indication of the value of the information to the organization. Some examples of 
possible quantitative valuations where given in chapter 5.2.3 when analyzing the 
cases.  
 
As previously mentioned in this thesis, information has a value based on its use and 
the situation it is used in, therefore table 7 gives an example of how a qualitative 
value can be associated with a situation where information is not available and/or 
reusable for defense purposes. The table identifies several stages of severity 
portraying the groups collected view on the information readiness, accounting for e.g. 
risk aspects, medicine class and market situation.  As an example if the reason for the 
valuation is operational impact and/or potential liability the proactive thinking in the 
Losec case is comparable to having ranked the information value as 4 or 5 and based 
on that made a decision on constructing a safety database. In the same way a 
conclusion can be made from the Bayer case that an information valuation was not 
done or at least the information was not ranked for defense purposes. 
 
 
Possible results if CR related information are not available or 
reusable when an issue occurs 
Qualitative value 
for valuation 
Medicine can give adverse event that are non life threatening 
 
1 
Medicine can give adverse event that are non life threatening but 
medicine can be marginally effected on the market 
2 
Medicine can be identified as ineffective and possibly harmful 
resulting in significant sales drop and market loss 
3 
Medicine can be confirmed to give serious adverse events resulting in 
withdrawal from the market 
4 
Medicine can be linked to causing harm and deaths to third party, 
resulting in organizational liability 
5 
 
Table 7: Information value related to the severity of the issue and the readiness of CR information 
(liability and/or operational impact) 
 
 
Going forward with the process the aforementioned risk factors (table 6), which can 
affect information value, are identified in relation to the reason for the information 
value. These risk factors are used in order to identify possible limitation of the 
information and its management. The focus on a relevant risk factor being, reusability, 
confidentiality, integrity or availability (or a combination there of) is put in the center 
of attention and used in order to identify possible means for defense e.g. medicine, 
organization etc.  
 
Having gone through the valuation process and approached a value for the 
information an assessment can be made to determine the extensiveness of the 
commitment needed for risk evasion. As suggested in the beginning of this thesis the 
valuation can be used to support a decision to invest in appropriate IT/IS to secure and 
uphold high value of information assets, through availability, confidentiality, integrity 
and reusability. 
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6 Conclusions 
This thesis has discussed mainly the possibility of valuing information in relation to 
risk analysis and its management as well as how the valuation can be used in practice 
to identify and appreciate information as a valuable asset. The work has resulted in a 
conclusion that the effort to value information is not entirely problem free, although at 
least theoretically, it is possible to establish information value. The question arises on 
how relevant the valuation is and to whom it has value, which is precisely one of the 
deciding factors that need to be looked at when a valuation work begins. 
 
Within AstraZeneca clinical research (CR) information has been identified as a 
valuable resource deserving special attention in order to reach its full potential for the 
organization. Since, CR information is a foundation for medicine development it leads 
to the question at issue “What is the value of Clinical Research information from a 
risk management perspective at AstraZeneca?” where the purpose was to establish an 
approach to valuing CR information at AstraZeneca accounting for risk management 
issues. The main conclusion of the thesis, for the purpose of the question at issue, 
turned out to be that information value can be seen as multidimensional therefore 
based on several reasons different information value can be established. The reasons 
identified where; exclusive possession, utility, cost or cost of recreation, potential 
liability and operational impact, as a result several indicators for qualitative and/or 
quantitative information value where identified. The scope of the risk is seen as being 
manageable by focusing on one or more of the four risk factors identified; reusability, 
confidentiality, availability and integrity, which can directly effect information value 
in a positive or negative way. Therefore, AstraZeneca has to decide which reason(s) 
for valuation is relevant, based on the information to be valued, and have a special 
focus on the risk factors identified as affecting the valuation.  
 
With reference to the first sub question “What methods are there for valuing clinical 
research information?” where the purpose was to explore suitable methods for 
valuing clinical research information, several candidate methods were explored and 
evaluated. The various methods for valuing information that where evaluated did in 
fact prove to a large extent non suitable for valuing clinical research information but 
having some usability for information valuation in other respect. This can be seen in 
both the theoretical framework and the analysis chapter.  
 
Methods like utility value, historical cost and various knowledge management 
methods are not practical to use when it comes to valuing clinical research 
information as mentioned earlier in the thesis. The focus of some of the more 
advanced methods is on measuring the value of knowledge management initiatives, 
intellectual capital (employee knowledge and expertise, customers), information value 
in decision-making, transaction value and information in use. The first two 
methodologies proved to be based on to broad perspectives with vague relation to 
information valuation, treating information valuation in a more general sense. 
Information value for decision-making as well as transaction value is irrelevant for the 
type of information in this thesis while information in use value can be seen requiring 
extensive follow-up on how information is used (access time, access frequency and 
relevancy) which can be misleading.  
 
Gunnar Gunnarsson & Jökull M. Steinarsson  Approaching Information Valuation 
 57 
 
The second sub question “How does clinical research information support risk and 
issue management at AstraZeneca?“ had the purpose of finding out how CR 
information supports risk and issue management that could be used for establishing 
the value of CR information. Clinical research information can be said to hold 
significant value to AstraZeneca when it comes to supporting risk and issue 
management but needs to be available and in a reusable state to minimize the risk of 
liability and operational impact. Presently the information is not in an optimal state 
for reuse where the information can be said to be somewhat spread between 
departmental, central (safety) and local sales office databases e.g. not supporting cross 
referencing of CR information,  data and projects. The future plans of consolidated 
clinical data storage (CCDS) improves the support for handling risk and issue 
management as is supported within the case studies. 
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7 Discussion 
Information valuation has been a fashionable topic in business and technology related 
literature with extensive references to methods and methodologies for valuing 
information. On the other hand, the various methods referred to in the literature 
primarily refer to knowledge management (KM) methods, which have been presented 
and put to use by known KM leaders (Sveiby, Edvinsson, Kaplan & Norton etc.) as 
well as various other information value authors (some mention in this work) with 
different approaches and reasons for the valuation. Nevertheless, it seems that 
information is merely a small part of a larger context within most available methods. 
Therefore it seems that relatively little progress has been made in the area of 
presenting a practical model for the value of information. Regardless of the amount of 
literature available, referring to valuation methods e.g. Edvinsson (1997) where he 
measures the value of knowledge and intellectual capital; Kaplan & Norton (1992) 
measure the company’s performance by indicators that are bases on the strategic 
objectives of the firm (financial, internal, customer, growth and learning). Sveiby 
(1997, 2001) measures the success of knowledge management initiatives. Skyrme 
(2002) and Broadbent (1992) measure the value of information centers. These 
methods seem to have that in common that they do not succeed in isolating the 
information value, merely touch upon it as a part of a larger context. Other known 
information valuation methods available where not deemed suitable for valuing 
clinical research (CR) information e.g. due to their focus on valuing information in 
trade, transaction value (utility) and information based on decision making to name 
some. At the same time various authors in the literature discredit all of the information 
valuation methods available, demonstrating in fact, that there is a shortage of suitable 
methods for valuing information in use within organizations. 
 
7.1 Reflecting on the work 
In this work a value of clinical research information has not been established due to 
the aforementioned reasons. The result of this work became a more general reflection 
on how organizations can approach valuing information based on the reason for its 
valuation in order to harness its full potential but also identifying several risk factors 
that can be associated with information value. The bottom line is that for valuing 
information in a successful manner it requires a complex and extensive operational 
focus on how information is used, how frequently and how users rank (value) 
information, within the organization as well as how information affects different 
organizational functions. The approach mentioned requires a different and broader 
focus identifying available technologies that are appropriate to measure and monitor 
information use (e.g. Balanced scorecard with indicators, Knowledge Expert Systems 
with tacit knowledge focus), but deemed inappropriate by the authors for the scope of 
this thesis. 
 
When reflecting on the methods identified and presented in this thesis it became clear 
that they could not be fully exploited as presented in theory. The historical cost 
method referred to in chapter 2.2.3 was not used to its full extent for valuing 
information. In the thesis historical cost of CR information could be used in order to 
apply the method, but use statistics need also to be established, among others, which 
was not deemed appropriate in the scope of this work. This would have required a 
Gunnar Gunnarsson & Jökull M. Steinarsson  Approaching Information Valuation 
 59 
 
considerably investigation into information use and available technology tools. In 
theory this method could be used within organizations but as pointed out in chapter 
1.5 Expected results, the benefits could probably be seen in the valuation process 
itself rather than in the quantitative value of the information.  
 
According to McGee & Prusak (1993) information is infinitely reusable and its value 
is determined by its user and the more information is used the more valuable it gets 
(Glazer, 1993). The authors of this thesis agree that information value can be stated as 
such, therefore it could be beneficial for certain type of information to base its value 
on how information is eventually used (e.g. how often, in what context, how many use 
it, relevance). Research on this subject has been done with focus on information 
access, access time, search redundancy and time per access to establish a relation 
between quantitative and qualitative measures of information use (Booske & Sainfort, 
1998) but the application seems imperfect and requiring extensive information 
technology effort to be workable.  
 
Glazer’s method of utility value can be used to value information that has monetary 
transactional value, i.e. information that generates revenue or can be referred to as 
being a part of a product or an asset. The utility value approach is used in order to 
show that the method can be partly applied when referring to the value of information 
in use. The reason utility value cannot be applied as presented by Glazer is that CR 
information does not generate any revenue on its own but has a utility value of a more 
qualitative character. 
 
The main problems the authors encountered during the work on this thesis can be said 
to be twofold, lack of relevant literature related to the question at issue (e.g. case 
studies) and the broad scope of the empirical work, providing a more qualitative 
knowledge to support the information valuation concept. Perhaps a closer encounter 
with the information would prove a more successful approach in order to generate a 
more precise and practical results to the question at issue. Further problems that where 
encountered are related to associating risk and information value, which lead to a 
more general qualitative approach to the subject. The reason being high uncertainty of 
future events, together with differences in risk between drug classes, leads to 
difficulty in establishing a practical value that wouldn’t be misunderstood.   
 
7.2 Further studies 
Valuing information is an extensive topic, which can be studied from many different 
angles. During the course of this work several interesting angles have been identified 
as being applicable for further development and studies.  
 
o Apply the approach presented in this thesis with the purpose; firstly, to see if 
the approach can be applied as stated. Secondly, to demonstrate if the process 
of going through the valuation is in fact more important than arriving at a 
specific value, e.g. monetary value.    
 
o Go through a decision analysis to establish how clinical research information 
support decision making when deciding on the validity of a project or further 
studies. 
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o Establish the value of information based on historical cost adjusted by its 
usage, shelf life and accuracy.  
 
o Follow how clinical research information effects the operation of the 
organization by establishing indicators that can be monitored (e.g. balanced 
scorecard) 
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